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Therapies addressing multiple stages of Plasmodium falciparum life cycle are highly desirable for
implementing malaria elimination strategies. MMV019918 (1, 1-[5-(4-bromo-2-chlorophenyl)furan-2-
yl]-N-[(piperidin-4-yl)methyl]methanamine) was selected from the MMV Malaria Box for its dual ac-
tivity against both asexual stages and gametocytes. In-depth structure-activity relationship studies and
cytotoxicity evaluation led to the selection of 25 for further biological investigation. The potential
transmission blocking activity of 25 versus P. falciparumwas conﬁrmed through the standard membrane-
feeding assay. Both 1 and 25 signiﬁcantly prolonged atrioventricular conduction time in Langendorff-
isolated rat hearts, and showed inhibitory activity of Ba2þ current through Cav1.2 channels. An in silico
target-ﬁshing study suggested the enzyme phosphoethanolamine methyltransferase (PfPMT) as a po-
tential target. However, compound activity against PfPMT did not track with the antiplasmodial activity,
suggesting the latter activity relies on a different molecular target. Nevertheless, 25 showed interesting
activity against PfPMT, which could be an important starting point for the identiﬁcation of more potent
inhibitors active against both sexual and asexual stages of the parasite.
© 2018 Elsevier Masson SAS. All rights reserved.gy, Chemistry and Pharmacy,
gy, Chemistry and Pharmacy,
gemma@unisi.it (S. Gemma).
work.
served.1. Introduction
Despite recent advances in the ﬁeld of antimalarial treatment,
malaria is still responsible for a high number of infections and
related deaths in tropical and sub-tropical regions [1]. The
A. Vallone et al. / European Journal of Medicinal Chemistry 150 (2018) 698e718 699antimalarial agenda has currently shifted from malaria control to
eradication/elimination strategies. To reach this ambitious goal and
to complement appropriate vector-control measures, such as lar-
vicidal compounds and insecticide-treated bed nets, prioritization
of new approaches, targeting the transmission stages of Plasmo-
dium falciparum life cycle (i.e. the gametocytes) is necessary [2].
Development of dual acting drugs active against asexual intra-
erythrocytic parasites, responsible for the clinical symptoms of
malaria, and gametocytes, the sexual forms of the parasite
responsible for malaria transmission, is a challenging goal but
necessary for the implementation of the above-mentioned
strategies.
High-throughput screening (HTS) assays have been successfully
applied to P. falciparum asexual stages for the discovery of novel hits
endowed with innovative modes of action [3e14]. Moreover, such
approaches have been adapted for the discovery of compounds
active as gametocytocidal agents [15e24]. Screening campaigns
using these assays allowed a better analysis and characterization of
the anti-gametocyte properties of known antimalarials and for the
discovery of potential hit compounds useful for the development of
transmission-blocking therapies [25]. The implementation of novel
methodologies of phenotypic screening for gametocytocidal com-
pounds was recently boosted by the non-proﬁt foundation Medi-
cine for Malaria Venture (MMV), which produced and delivered a
collection of 400 commercial compounds divided into 200 drug-
like and 200 probe-like structures, i.e., the “Open Access Malaria
Box” [26]. The structures present in the Malarial Box were selected
using results from phenotypic screening of large compound col-
lections against P. falciparum [3,27,28]. These phenotypic screens
identiﬁed nearly 20,000 compounds that were active against
P. falciparum 3D7 and endowed with reasonable toxicity. Selection
criteria for compounds included in the Malaria Box were com-
mercial availability, maximization of the structural diversity, and
potency.
A cell-based assay with P. falciparum gametocytes expressing a
potent luciferase and a lactate dehydrogenase (LDH)-based game-
tocyte assay were used to screen known antimalarial compounds
and those of the MMV Malaria Box [23,25,26]. From this initial
study, compound MMV019918 (1, Chart 1) [26] demonstrated dual
activity against P. falciparum asexual and sexual stages with
IC50< 1000 nM; an in vitro IC50< 1000 nM against late stages
Plasmodium gametocytes consistently found in different published
assays (and also in the structurally related compound N-[(5-(3-
chloro-4-ﬂuorophenyl)furan-2-yl)methyl]-N,N0-dimethylpropane-
1,3-diamine (MMV020505, 2)) [25]; activity on both male and fe-
male NF54 gametes; and properties favorable for drug develop-
ment, including a low molecular weight and a scaffold suitable for
optimization of efﬁcacy. Starting from compound 1 and combining
synthetic and biological efforts, we investigated the structure-Chart 1. Structure of the reference compounds 1,2 and of the analogue 25.activity relationships (SAR) of this class of compounds with the aim
of understanding the general structural features important for the
observed activity. Our goal was also to investigate and possibly
improve the toxicity proﬁle of the prepared analogues since the
selectivity index (SI) of 1 was rather low based on the available
information, and a certain degree of hERG activity (83% of inhibition
at 50 mM) was also known for this compound [25].
The SAR investigation of 1 was based on the possibility of dis-
connecting its scaffold into three modules: a hydrophobic head, a
heterocyclic linker, and a pendant basic chain (Chart 1). We intro-
duced different substituents, at the hydrophobic head to explore
the role of the two halogen substituents, replaced the central linker
with different heterocyclic scaffolds, and replaced the cyclic
piperidine moiety with linear lateral chains. Compound 25,
showing comparable potency with respect to 1, characterized by
the presence of and extra aromatic ring at the hydrophobic head
and endowed with reasonable TC50, was then selected for further
biological studies.
2. Results and discussion
2.1. Chemistry
We identiﬁed a synthetic strategy for the preparation of the hit
compound 1 that was also suitable for the preparation of a broad
series of analogues bearing different substitution patterns at the
phenyl ring.
As displayed in Scheme 1, the ﬁrst step to the synthesis of 1 and
analogues 8e12 was a Suzuki-Miyaura coupling between arylio-
dides 3a-f and the organoboronic acid 4 [29] to afford aldehydes
5a-f. In the case of derivatives 5a,c,d, this palladium-catalyzed
cross coupling reaction turned out to be exquisitely regioselective
for the formation of reaction products arising from attack at the
most reactive iodine with respect to other halides. In the subse-
quent steps of the synthesis, aldehydes 5a-f and 6 (in turn obtained
from 5f by deprotection) were reacted with the primary amine 7
and the resulting imine intermediates were reduced using sodium
cyanoborohydride. Final removal of the piperidine protecting group
upon exposure to acidic conditions led to the ﬁnal compounds 1
and 8e12.
Amine 7 was prepared starting from N-Boc-piperidone 13,
which was subjected to a Wittig reaction using (methoxymethyl)
triphenylphosphonium chloride and sodium bis(trimethylsilyl)
amide [30] resulting in an intermediate vinylmethyl ether that was
hydrolyzed using cerium chloride and sodium iodide [31] to afford
aldehyde 14. This latter compound was reduced to the corre-
sponding alcohol, which was converted into methanesulfonate and
reacted with sodium azide to furnish 15. The ﬁnal catalytic hy-
drogenation, using palladium on carbon, led to the formation of the
desired piperidinyl-methanamine 7 in satisfactory yield.
Because of the unavailability of the starting aryliodides, a second
set of compounds, modiﬁed at the hydrophobic head, was syn-
thesized using a different chemical route (Scheme 2). For the syn-
thesis of aldehydes 5a and 18b-e, the Meerwein arylation protocol
[32], consisting in a copper-catalyzed arylation of furan derivatives
with arenediazonium salts, was conveniently used. According to
this procedure, anilines 16a-e were converted into the corre-
sponding diazonium salts, and these latter intermediates were
coupled in situ with furan-carboxaldehyde 17. Intermediates 5a
and 18b were also submitted to a Suzuki coupling to afford the
biphenyl derivatives 19a,b, respectively. Aldehydes 5a,18b-e, and
19a,bwere ﬁnally converted into ﬁnal compounds 21e26 using the
protocol previously described for the introduction of the pendant
basic chain.
Starting from 16a,b, the Meerwein arylation protocol was also
Scheme 1. General synthesis of compounds 1, 8e12.a
aReagents and conditions: (a) Bis(triphenylphosphine)Pd(II) dichloride, aq. Na2CO3, dimethoxyethane (DME), EtOH, reﬂux, 12 h, 33e83%; (b) BCl3, dichloromethane (DCM), 78 C,
3 h, 55%; (c) i. MeOH, reﬂux, 12 h; ii. NaBH4, 0 C, 1 h; (d) 1 N HCl, MeOH, 25 C, 4 h, 60e75% over two steps; (e) i. MeOCH2PPh3Cl, NaN(SiMe3)2, 25 C, 12 h, 40%; (f) CeCl3, NaI, MeCN,
reﬂux, 12 h, 87%; (g) NaBH4, MeOH, 25 C, 1 h, 100%; (h) MeSO2Cl, Et3N, DCM, 25 C, 12 h, 99%; (i) NaN3, N,N-dimethylformamide (DMF), 90 C, 12 h, 70%; (j) Pd/C, H2 (1 atm), MeOH,
25 C, 3 h, 95%.
Scheme 2. Synthesis of analogues 21e26 and 29,30.a
aReagents and conditions: (a) i.16a-e, HCl 37%, NaNO2, H2O, 0 C, 1 h; ii.17 (or 27), CuCl2, acetone, 25 C, 12 h, 70e90%; (b) Pd(OAc)2, PPh3, aq. Na2CO3, PhB(OH)2, toluene, reﬂux, 12 h,
63e85%; (c) i. 7, MeOH, reﬂux, 12 h; ii. NaBH4, 0 C, 1 h; (d) 1 N HCl, MeOH, 25 C, 4 h, 51e80% over two steps.
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28a,b. These latter compounds were then converted to the ﬁnal
compounds 29,30, representing a ﬁrst set of analogues of the hit
compound 1 bearing modiﬁcation of the heterocyclic linker.
For the synthesis of the benzothiophene derivative 32 (Scheme
3), aldehyde 31 [33,34] was submitted to the reductive amination
reaction, which upon acidic Boc deprotection, led to the prepara-
tion of the desired ﬁnal compound 32. Compounds bearing ﬁve-
membered heterocycles 37 and 38 were prepared starting from
arylhydrazide 33. Cyclization of 33 was performed through a Pel-
lizzari-like reaction, consisting in the condensation between acyl
hydrazine 33 with benzyl amine [35]. Only the dehalogenatedproduct 34 was obtained from this reaction. The alcoholic function
of 35, introduced by a Prince electrophilic addition using formal-
dehyde, was activated to the corresponding chloride 36awhichwas
alkylatedwith amine 7. OxidativeN-debenzylation [36] followed by
acid-mediated deprotection of the Boc-group furnished the triazole
37. For the synthesis of oxadiazole 38, the chloromethyl interme-
diate 36b was obtained by cyclization of 33 in the presence of
chloroacetic acid and POCl3 [37].
Another substitution of the central linker is represented by the
pyridine derivative 43 (Scheme 4). A C2 selective Suzuki-Miyaura
arylation was applied starting from the commercially available 2-
bromo-6-methylpyridine 39 and 4-triﬂuoromethylphenylboronic
Scheme 3. Synthesis of central linker analogues 32, 37, 38.a
aReagents and conditions: (a) i. 7, MeOH, reﬂux, 12 h; ii. NaBH4, 0 C, 1 h; (b) 1 N HCl,
MeOH, 25 C, 4 h; (c) N,N-dimethylformamide dimethyl acetal (DMF-DMA), MeCN,
50 C, 1 h, then BnNH2, AcOH, 120 C, 12 h, 60%; (d) aq. CH2O, reﬂux, 12 h; (e) pyridine,
SOCl2, DCM, 0 C, 3 h, 50%; (f) POCl3, ClCH2CO2H, reﬂux, 12 h, 20%; (g) 7, K2CO3, KI (cat.),
MeCN, reﬂux, 1 h, 72%; (h) tBuOK, DMSO, THF, O2, 25 C, 2 h, 87%.
Scheme 4. Synthesis of pyridine derivative 43.a
aReagents and conditions: (a) Pd(OAc)2, PPh3, K2CO3, 7:3 DMF/H2O, reﬂux, 12 h, 81%;
(b) NBS, AIBN (cat.), CCl4, reﬂux, 12 h, 30%; (c) 7, K2CO3, MeCN, reﬂux, 12 h, 20%; (d) 1 N
HCl, MeOH, 25 C, 4 h, 98%.
Scheme 5. Synthesis of analogues modiﬁed at the protonatable side chain.a
aReagents and conditions: (a) i. NH2(CH2)3NMe2, DCM, 25 C, 1 h; ii. NaBH(OAc)3, 25 C,
24 h, 85%; (b) (Boc)2O, Et3N, MeOH, 25 C, 4 h, 43% over two steps; (c) MeI (for 47) or
BnBr (for 48), acetone, reﬂux, 72 h, 58e60%; (d) 1 N HCl, MeOH, 25 C, 4 h, 94e95%.
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subjected to a bromination reaction using N-bromosuccinimide
(NBS) and azobisisobutyronitrile (AIBN). The brominated interme-
diate 42 was used to alkylate amine 7. The ﬁnal Boc deprotection
gave in high yield the ﬁnal derivative 43.
The open-chain analogue 45 was synthesized as described in
Scheme 5 starting from intermediate 5a and the commercially
available N,N0-dimethyl-1,3-propanediamine 44. Starting from 18b,
reductive amination with 44 followed by protection of thesecondary amine as Boc-derivative led to intermediate 46. The
tertiary amine was subsequently converted to a quaternary
ammonium salt using benzyl bromide and iodomethane, respec-
tively. The ﬁnal Boc-deprotection using acetyl chloride and meth-
anol gave the two ﬁnal derivatives 47 and 48 in satisfactory yields.
2.2. Antiplasmodial and gametocytocidal activities and structure-
activity relationships
The antiplasmodial activity of the newly synthesized com-
pounds was tested against two laboratory P. falciparum strains, the
chloroquine-sensitive (CQ-S) D10 and the chloroquine-resistant
(CQ-R) W2, according to the described procedures [38,39]. Activity
against gametocytes (GCT) was assessed using a luciferase-based
assay, as previously described [23].
Selected compoundswere also tested against P. falciparum strain
NF54 asexual blood stage parasites using a Sybrgreen DNA repli-
cation assay. NF54 gametocyte assays were performed using re-
porter strain NF54-HGL [40]. The results of the biological assays are
reported in Tables 1e3.
2.2.1. Hydrophobic head
In order to understand if the antiplasmodial and anti-
gametocytocidal activities depended upon the substitution pattern
of the aromatic head, we removed one or both alogens of 1 (com-
pounds 9, 22 and 8, respectively). Moreover, we inverted the po-
sition of the Cl or Br substituent obtaining the regioisomeric
derivative 21, and introduced different electron-withdrawing
groups at the p-position such as eF (10), -CN (24), and eCF3 (23).
We also placed electrondonating and H-bond donor/acceptor
groups such as -OMe and eOH (11 and 12, respectively). A second
aromatic ring, giving rise to regioisomers 25 and 26 was placed
along the halogen present in the original structure in order to
explore the tolerance of the system to bulky substituents. From this
study we derived interesting SARs: as shown in Table 1, the sub-
stituents at the hydrophobic head seems to play a key role for in
vitro activity against both asexual and sexual parasite stages. In
particular, the presence of both halogens is important for activity
since the unsubstituted analogue 8, as well as the mono-haloge-
nated derivatives 9, 10 and 22 are less potent antiplasmodial and
gametocytocidal agents than the hit compound 1. Inversion of
chlorine and bromine seems not to have a signiﬁcant effect on
potency as demonstrated by the regioisomeric derivative 21.
Table 1
Asexual and sexual stages activity (IC50, mM) of compounds modiﬁed at the hydrophobic head.
Structure D10a W2b GCT: 3D7elo1-pfs16-CBG99 NF54a GCT: NF54-HGL
IC50 (mM)c
1 0.77 2.3 1.2 n.t.d n.t.
8 3.5 9.1 8.6 n.t. n.t.
9 1.1 8.0 4.4 n.t. n.t.
10 2.1 7.9 6.0 n.t. n.t.
11 10.0 >15 11.8 n.t. n.t.
12 4.4 9.6 8.3 0.26 0.29
21 0.51 1.87 1.1 n.t. n.t.
22 2.1 4.3 5.9 n.t. n.t.
23 0.41 1.5 1.9 n.t. n.t.
24 1.1 6.3 18.4 n.t. n.t.
25 0.88 2.4 1.4 0.67 0.043
26 1.0 3.0 1.4 n.t. n.t.
Chloroquine 0.026 0.31 e n.t. e
Epoxomycin e e 0.007 e 0.0007
Methylene blue e e 0.030 e n.t.
a CQ-S strain.
b CQ-R strain.
c IC50 values are themean of at least three experiments in duplicate; differences in the experimental conditions, parasite strain/stage, andmethods of detectionmay account
for the different IC50 observed in the two gametocyte assays. S. D. were within 20% of the mean.
d n.t.¼ not tested.
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the triﬂuoromethyl derivative 23maintained a potency similar to 1,
while with a cyano group at para position (24) a drop of potency
was observed, especially against the gametocytes. Also the intro-
duction of electron-donating substituents such as methoxy (11) or
hydroxyl (12) groups resulted in a dramatic drop of potency against
gametocytes. Interestingly, introduction of an aromatic ring ateither C2 or C4, as in compounds 25 and 26, respectively, was
tolerated and antiplasmodial and gametocytocidal activities com-
parable to the hit compound 1 were observed.
2.2.2. Heterocyclic linker
The role of the heterocyclic tether on activity was evaluated
through the synthesis of several 5-membered heterocyclic systems
Table 2
Asexual and sexual stages activity (IC50, mM) of compounds modiﬁed at the heterocyclic linker.
Structure D10a W2b GTC
3D7elo1-pfs16-CBG99
NF54a GTC
NF54-HGL
IC50 (mM)c
29 0.73 2.2 0.85 0.28 0.020
30 0.53 1.4 0.83 0.42 0.028
32 1.0 1.5 1.4 0.73 0.053
37 >13 >13 >13 n.t.d n.t.
38 >13 7.9 >26 n.t. n.t.
43 0.46 3.4 4.0 n.t. n.t.
a CQ-S strain.
b CQ-R strain.
c IC50 values are themean of at least three experiments in duplicate; differences in the experimental conditions, parasite strain/stage, andmethods of detectionmay account
for the different IC50 observed in the two gametocyte assays. S.D. were within 20% of the mean.
d n.t.¼ not tested.
Table 3
Asexual and sexual stages activity (IC50, mM) of compounds modiﬁed at basic side
chain.
Structure D10a W2b GTC:
3D7elo1-pfs16-CBG99
IC50 (mM)c
45 1.2 1.4 1.1
47 2.5 5.5 >24
48 0.55 0.66 4.8
a CQ-S strain.
b CQ-R strain.
c IC50 values are the mean of at least three experiments in duplicate. S. D. were
within 20% of the mean.
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triazole- (37), and oxadiazole- (38) derivatives (Table 2). The pyri-
dine-derivative 43 was conceived in order to explore the effect on
activity of a 6-membered ring bearing an heteroatom able to
function as H-bond acceptor analogously to the furan oxygen, while
the fusion of the pendant phenyl ring with the thiophene of 29
resulted in the benzothiophene-derivative 32. The sulfur-basedheterocycles were tolerated and in some cases led to a slight
improvement of activity. Also the six-membered pyridine-deriva-
tive (43) showed reasonable potency, especially against the CQ-S
strain, while the other heterocycles investigated led to a dramatic
drop of potency.
2.2.3. Pendant basic chain
Derivative 45, bearing the same basic chain as 2, showed a po-
tency comparable to 1 (Table 3). The ammonium quaternary salts
47 and 48were synthesized in an attempt to increase potency since
quaternary ammonium salt derivatives were previously displayed
as interesting antiplasmodial agents [41]. Both compounds dis-
played a drop of potency against gametocytes. Interestingly, benzyl
derivative 48 maintained its potency against the asexual forms of
the parasite, but not against the gametocytes.
For all compounds synthesized, molecular properties calculated
in silico by QikProp (version 4.3; Schr€odinger, LLC: New York, 2015)
such as lipophilicity, polar and solvent accessible surface areas,
solubility and membrane permeability were all in the recom-
mended range values for known drugs (Table S1 in the Supple-
mentary Information ﬁle).
2.3. In vitro cytotoxicity
After investigation of SAR, we selected a representative set of
analogues characterized by various degrees of antiplasmodial and
gametocytocidal potency for cytotoxicity assays. Cell viability was
evaluated in vitro against NIH3T3 after 24 h of contact, by Neutral
Red Uptake (NRU) test. The cell line has been chosen because is a
standard ﬁbroblast cell line.
Results of cytotoxicity tests are reported in Table 4. Compounds
11, 23 and 25 resulted the least toxic of the series. The reasonable
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presenting an extra aromatic ring that could be further decorated,
prompted us to select this compound for further biological inves-
tigation as detailed in the next paragraphs.
2.4. Standard membrane-feeding assay
The evaluation of the ability of compounds to inhibit the
development of oocysts in the mosquito and thus reduce the
mosquito's ability to transmit malaria parasites can be conﬁdently
assessed using the standard membrane-feeding assay (SMFA)
which remains the assay of choice for this kind of investigation. The
assay consists in feeding cultured P. falciparum gametocytes to
Anopheles mosquitoes in the presence of the test compound and
measuring subsequent mosquito infection. The hit compound 1
was recently shown to have an EC50 in the SMFA assay of 0.07 mM
[21]. Evaluation of compound 25 in the SMFA assay resulted in an
IC50 of 0.21 mM on infection intensity, and 0.83 mM on infection
prevalence at a baseline infection intensity of 30 oocysts/midgut
(Fig. 1). These data conﬁrm that the gametocytocidal activity of 25
as observed in the NF54 gametocyte luciferase assay translates into
an inability to infect the mosquito vector. The IC50 on infection
intensity is slightly higher than expected on basis of the NF54
gametocyte luciferase assay. This may be explained by the differ-
ence in incubation time (24 h in the SMFA vs 72 h in the gametocyte
assay) and a relatively slow mode of action of the compound.
2.5. Evaluation of activity of compound 25 against P. berghei liver
stages
We also investigated if compound 25 could have activity against
the liver stages of P. berghei parasites. Primary mouse hepatocytes
have been infected with mCherry expressing P. berghei sporozoites.
2 h post infection (hpi) the cells were exposed to different con-
centrations of 25 for 48 hpi with medium change at 24 hpi. Neither
parasite numbers (Fig. 2A) nor parasite sizes (Fig. 2B) were signif-
icantly inﬂuenced at the concentration tested. Compound 25 was
also used to analyze detached cell formation, which is an in vitro
assay for ﬁnal development (equivalent to merosome formation in
vivo). Living parasites were counted at 48 h and from the same
wells detached cells at 65 hpi evaluated. Neither concentration
tested signiﬁcantly inhibited detached cell formation, as indicated
by the similar rates of detached cells compared to DMSO-treated
control cells at 48 h (Fig. 2C).
2.6. Evaluation of cardiac toxicity and calcium antagonist activity
of 1 and 25
Considering the potential hERG liability previously highlighted
for compound 1, we decided to evaluate the cardiotoxic potential of
both compounds 1 and 25. Accordingly, their effect on cardiac
mechanical function and electrocardiogram (ECG) in Langendorff-
isolated rat hearts was assessed, as previously described [39,42].
Compounds 1 and 25 reduced left ventricular pressure (LVP) in a
concentration-dependent manner (Fig. 3), leaving unaltered coro-
nary perfusion pressure (CPP, data not shown). They signiﬁcantlyTable 4
Cytotoxic activity against 3T3 cell lines of selected compounds evaluated after 24 h
of incubation by NRU test.
Cpd 11 12 21 23 25 26 29 30 45
TC50 (mM)a 53 7 <5 50 20 5 <5 <5 5
a Data are expressed as mean of three experiments repeated in six replicate. S.
D.are within 5% of the mean.prolonged atrioventricular conduction time (PQ) and intraventric-
ular conduction time (QRS) in ECG at the maximum concentration
tested (10 mM; Table 5). However, QTc values did not vary over the
drug range tested (Table 5). Compound 1 signiﬁcantly decreased
heart rate (HR), increased cycle length (RR) interval (Table 5) and
caused a sinus arrhythmia in 3 out of 4 hearts.
Since channel blockers, by inhibiting the Cav1.2 channel cur-
rents, may prolong conduction and refractoriness in the atrioven-
tricular node [43], the increased PQ interval obtained in presence of
both compounds prompted us to investigate the effects of 1 and 25
on Cav1.2 channel currents. Compound 1 inhibited IBa1.2 (Ba2þ
current through Cav1.2 channels), measured at 0mV from a holding
potential (Vh) of 50mV, in a concentration-dependent manner
(Fig. 4). At 10 mM concentration, inhibition amounted to 57%.
Compound 25 blocked the current at 30 mM concentration and
showed an IC50 value of 3.3± 0.5 mM (n¼ 5).
2.7. In silico approach for target identiﬁcation of compounds 1 and
25
Despite recent advances in the ﬁeld, target identiﬁcation re-
mains a challenging task that could be approached through several
methodologies such as direct biochemical methods, genetic in-
teractions, computational approaches, or a combination of
methods. We performed a preliminary computational investigation
aimed at identifying a potential target of compounds 1 and 25 from
structures in the Protein Data Bank (PDB). As a part of a broad
investigation aimed at repurposing FDA-approved drugs against
malaria, we prepared all the P. falciparum X-ray crystal structures
present in PDB at May 2016, to be used in a high-throughput
docking (HTD) procedure for identifying potential antimalarial
drug-targets targeted by known drugs. Employing a reverse-dock-
ing procedure (also known as reverse virtual screening or target
ﬁshing) [44], we retrieved from the PDB database (and prepared by
Protein Preparation Wizard as previously reported [42,45]) all en-
zymes and proteins relevant for the plasmodium biology, some of
which are established drug targets. Compounds 1 and 25were then
used to “ﬁsh” for potential targets by using Glide software [46e48].
The results of our in silico study for these compounds indicated a
very limited number of potential targets with low docking scores
among the examined docking complexes. Surprisingly, for one
protein (P. falciparum phosphoethanolamine methyltransferase;
PfPMT) we observed for both compounds signiﬁcant docking scores
and calculated ligand-binding energies, as found by Glide and
Prime (see Experimental part for further details) [46,49e51]. In
fact, for 1 and 25 we found computational scores (1, Glide XP
score¼10.52 kcal/mol, DGbind¼57.38 kcal/mol; 25, Glide XP
score¼11.28 kcal/mol, DGbind¼67.54 kcal/mol) comparable to
those found for sinefungin (Glide XP score¼13.16 kcal/mol,
DGbind¼84.77 kcal/mol) and S-adenosylmethionine (SAM) (Glide
XP score¼10.57 kcal/mol, DGbind¼82.42 kcal/mol), especially
for the docking scores. The most relevant differences were related
to the DGbind, for which we observed less negative values of 1 and
25with respect to the reference ligands. So, given the satisfactory in
silico scores, we decided to test them against PfPMT along with two
related derivatives 24 and 48.
2.7.1. Evaluation of 1, 25 and analogues as inhibitors of PfPMT
Compounds 1, 24, 25 and 48 were tested as potential inhibitors
of PfPMT using a radiochemical assay performed with puriﬁed re-
combinant protein, which was expressed and puriﬁed as previously
reported (Fig. 5A) [52,53]. Compounds 1, 24, and 48 showed weak
activity against PfPMT, while compound 25 displayed an inhibitory
effect against PfPMT with an IC50¼ 44.3± 5.4 mM (Fig. 5B). The
experimental data is in good agreement with the computational
Fig. 1. Compound 25 blocks transmission in the SMFA. A) Compound effect on the infection intensity. The ﬁgure shows luminescence activities 8 d post-infection of mosquitoes fed
on NF54-HGL gametocytes that were pre-incubated with compound 24 h prior to feeding. A total of 24 mosquitoes was analyzed for each experimental feed, and all feeds were
performed in duplicate. The ﬁgure shows the mean of the average signal intensities of each feed. Error bars indicate the standard error of the mean B) compound effect of infection
prevalence, or the proportion of mosquitoes that carry at least one oocyst. The ﬁgure shows average data from two independent feeds. Error bars indicate standard deviations.
Fig. 2. Compound 25 does not inhibit P. berghei liver stage schizont development in vitro. Different concentrations of 25were employed to treat mouse primary hepatocytes infected
with mCherry expressing P. berghei sporozoites were treated with different concentrations of 25. A. Parasite numbers per well at 48 h are shown (n¼ 4, SD) indicating no liver stage
activity of compound 25. B. Parasite sizes of one replicate of treated cells from A) are shown. C. Detached cells compared to DMSO-treated control cells at 48 h One-wayANOVAwith
Dunnet's Multiple Comparisons (*p  0.05, **p  0.01 ***p  0.001, ns/not signiﬁcant > 0.05) showed no signiﬁcant difference compared to the control treated cultures.
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compound among the tested molecules, although with slight
reduced activity with respect to the reference compounds [53].Considering that at the moment only few PfPMT inhibitors have
been described, mainly related to the natural substrate SAM,
compound 25 could be used as a starting point to develop PfPMT
Fig. 3. Effects of 1 and 25 on left ventricular pressure in Langendorff perfused rat
hearts. Concentration-effect relationship of 1 and 25 on LVP. On the ordinate scale,
response is reported as mmHg. Each value represents mean ± SEM (n¼ 4 hearts).
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output found by Glide software of 25 into the PfPMT active site. In
particular, the amino-groups of the compound may form hydrogen
bonds with D85 and R127 with the biaryl system ﬁtting into in a
hydrophobic sub-pocket and the furan group stacking with H132.
Notably, these interactions are part of the main contacts found for
the above-mentioned reference compounds [53].
Despite the interesting ﬁndings, the inhibition of PfPMT exper-
imentally observed did not correlated with the antiplasmodial and
gametocytocidal activity of the compound and from these data we
can rule out PfPMT as the target (or at least the main target) of this
series of compounds. Our results are in line with a study recently
published [25] in which PfPMT has been excluded as the target of 1
in an indirect yeast-mediated assay.3. Conclusions
Here we described a detailed SAR analysis of hit compound 1
and its analogue 25 for their activity against asexual and sexual life
cycle stages of P. falciparum. From our SAR studies, the electron
withdrawing substituents at the hydrophobic head were identiﬁed
as important for activity. Moreover, the presence of nitrogen-based
heterocyclic linkers resulted detrimental for activity being the
thiophene and the furan rings the best performing linkers. A small
set of side-chain analogues was explored highlighting that the
open-chain analogue retained antiplasmodial potency, while it was
interesting to note that among the two quaternary ammonium salts
prepared, the benzyl-derivate was active against the asexual life
cycle stage. Among the set of compounds synthesized, analogue 25
was selected for a more in depth biological investigation, due to its
antiplasmodial potency in the low micromolar range, reasonable
cytotoxicity and the presence of an extra aromatic ring that could
offer a handle for further scaffold decoration. In particular, com-
pound 25was active in the SMFA assay with potency comparable to
1. On the other hand, 25 did not show activity against P. berghei
hepatocytic life-cycle stage at the concentration tested, even
though this could be a species speciﬁc effect. Unfortunately, cardiac
toxicity was observed for both 1 and 25. Even though the biological
activity of 1 and 25 against gametocytes and asexuals P. falciparum
stages remains interesting and worth of further investigation,
exploitation of this scaffold will only be possible by identifying its
target at the molecular level. This is a necessary pre-requisite for
investigating if dissociation of in vitro toxicity from the speciﬁc
gametocytocidal and schizontocidal activities is a feasible task.
Accordingly, we reported herein our preliminary in silico study
devoted at identifying the target for this series of compounds.Driven from this studywe subsequently found that analogue 25 has
an interesting in vitro inhibitory activity against PfPMT, a key
enzyme for phospholipid biosynthesis in P. falciparum [54]. Com-
pound 25 could serve as a starting molecule, for the structure-
based design of novel inhibitors as potential antiplasmodial and
transmission-blocking agents.
4. Experimental section
4.1. Chemistry
Starting materials and solvents were purchased from commer-
cial suppliers and used without further puriﬁcation. Reaction
progress was monitored by TLC using silica gel 60 F254
(0.040e0.063mm) with detection by UV. Silica gel 60
(0.040e0.063mm) was used for column chromatography 1H NMR
and 13C NMR spectra were recorded on a Varian 300MHz, or a
Bruker 400MHz spectrometer using the residual signal of the
deuterated solvent as internal standard. Splitting patterns are
described as singlet (s), doublet (d), triplet (t), quartet (q), and
broad (br); the value of chemical shifts (d) are given in ppm and
coupling constants (J) in Hertz (Hz). Mass spectra were recorded
utilizing electron spray ionization (ESI) Agilent 1100 Series LC/MSD
spectrometer. Melting points were determined using a Büchi
Melting point B-540. Yields refer to puriﬁed products and are not
optimized. All moisture-sensitive reactions were performed under
argon atmosphere using oven-dried glassware and anhydrous sol-
vents. All compounds that were tested in the biological assays were
analyzed by combustion analysis (CHN) to conﬁrm the
purity> 95%.
4.1.1. 5-(4-Bromo-2-chlorophenyl)furan-2-carbaldehyde (5a)
Method A: To a solution of 3a (150mg, 0.47mmol) in a mixture
of dry DME (3mL) and dry EtOH (3mL), bis(triphenylphosphine)
palladium (II) dichloride (17mg, 0.02mmol) was added. After
30min, a solution of sodium carbonate (299mg, 2.82mmol) in H2O
(2mL) and a solution of 5-formyl-2-furanylboronic acid 4 (93mg,
0.66mmol) in dry EtOH (1.5mL) were added in this order. The re-
action was heated under reﬂux for 12 h. After this time, H2O (4mL)
was added at 25 C and the organic phase was extracted with EtOAc
(3 5mL), dried over sodium sulfate, ﬁltered and evaporated in
vacuo. The crude product was puriﬁed by ﬂash chromatography on
silica gel (2% EtOAc in petroleum ether) to give 5a as orange solid
(79 mg, 60%).Method B: To a suspension of 16a (1.0 g, 4.8mmol) in
H2O (20mL), HCl (37%, 2mL) was added. The resulting solutionwas
cooled at 0 C and a solution of sodium nitrite (397mg, 5.76mmol)
in H2O (2mL) was added dropwise. After 1 h, a solution of 17
(400 mL, 4.8mmol) in acetone (2mL) and solid copper (II) chloride
(128mg, 0.96mmol) were added. The mixture kept at 25 C for
12 h. EtOAc was added (3 10mL) and the organic phase was
separated, dried over sodium sulfate, ﬁltered and evaporated in
vacuo. The crude product was puriﬁed by ﬂash chromatography on
silica gel (2% EtOAc in petroleum ether) to give 5a as orange solid
(1.23 g, 90%). mp (EtOAc/n-hexane) 141e144 C; 1H NMR (300MHz,
CDCl3) d 9.69 (s, 1H), 7.88 (d, J¼ 8.6 Hz, 1H), 7.65 (s, 1H), 7.50 (d,
J¼ 8.6 Hz, 1H), 7.33 (d, J¼ 3.8 Hz, 1H), 7.30 (d, J¼ 3.8 Hz, 1H); 13C
NMR (75MHz, CDCl3) d 177.6, 154.6, 151.8, 133.7, 132.4, 130.7, 130.2,
126.8, 123.6, 123.0, 113.6. MS (ESI) m/z 308 [M þ Na]þ.
4.1.2. 5-Phenylfuran-2-carbaldehyde (5b)
Starting from 3b (100mg, 0.49mmol) and 4 (96mg, 0.68mmol),
the title compound was prepared following the procedure
described for the synthesis of compound 5a (Method A). The crude
product was puriﬁed by ﬂash chromatography on silica gel (5%
EtOAc in petroleum ether) to give 5b as a yellow oil (70mg, 83%).1H
Table 5
Effects of 1 and 25 on HR, RR, PQ, QRS and QTc in Langendorff perfused rat hearts.a
Cpd (mM) HR (BPM) RR (ms) PQ (ms) QRS (ms) QTc (ms)
1
25
None 247.05± 6.87
275.90± 5.43
242.23± 5.93
217.15± 3.38
42.63± 2.08
41.13± 1.64
14.35± 0.47
13.31± 0.62
80.07± 1.94
76.45± 1.15
1
25
0.1 256.15± 7.19
276.19± 5.33
235.08± 7.41
218.32± 4.37
42.29± 2.30
41.24± 1.65
14.25± 0.48
14.20± 0.61
81.51± 1.95
74.92± 1.01
1
25
1 258.35± 6.79
275.47± 4.14
232.48± 6.38
217.02± 3.57
42.50± 2.19
41.59± 1.60
15.80± 0.39
13.70± 0.43
80.93± 1.56
77.21± 2.25
1
25
3 257.71± 7.88
276.40± 3.59
233.90± 7.19
216.73± 2.48
47.90± 2.95
45.47± 2.58
17.46± 1.15
14.65± 0.91
82.10± 2.16
78.56± 3.86
1
25
10 222.74 ± 14.1*
259.41± 6.79
272.57 ± 17.8*
232.20± 5.83
67.50 ± 1.85**
65.08 ± 10.15**
23.75 ± 2.84**
17.91 ± 1.33**
80.99± 3.78
83.77± 4.58
a HR (frequency), RR (cycle length), PQ (atrio-ventricular conduction time), QRS (intraventricular conduction time), QTc (corrected overall action potential duration).
Bazett's formula normalized to average rat RR (QTc ¼ QT/(RR/f)1/2) [J. Kmecova, J. Klimas, Heart rate correction of the QT duration in rats, Eur. J. Pharmacol. 641 (2010)
187e192] was used to correct QT. Each value represents mean ± SEM (n ¼ 4 hearts).*P < 0.05,**P < 0.01, repeated measures ANOVA and Dunnett's post test.
Fig. 4. Effect of compounds 1 and 25 on IBa1.2 in single rat tail artery myocytes. Con-
centration-dependent effect of 1 and 25 at the peak of IBa1.2 trace. On the ordinate
scale, response is reported as percentage of control. Data points are mean ± SEM
(n¼ 3e6 cells, isolated from at least 3 animals).
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(ddd, J¼ 14.4, 7.9, 4.3 Hz, 3H), 7.28 (d, J¼ 2.4 Hz, 1H), 6.80 (d,
J¼ 2.4 Hz, 1H); MS (ESI) m/z 173 [M þ H]þ, 195 [M þ Na]þ.
4.1.3. 5-(4-Bromophenyl)furan-2-carbaldehyde (5c)
Starting from 3c (100mg, 0.35mmol) and 4 (65mg, 0.46mmol),
the title compound was prepared following the procedure
described for the synthesis of compound 5a (Method A). The crude
product was puriﬁed by ﬂash chromatography on silica gel (5%
EtOAc in petroleum ether) to give 5c as a yellow solid (60mg, 68%).
mp (EtOAc/n-hexane) 152e155 C; 1H NMR (400MHz, CDCl3) d 9.62
(s, 1H), 7.63 (d, J¼ 6.8 Hz, 2H), 7.53 (d, J¼ 4.8 Hz, 2H), 7.27 (d,
J¼ 3.6 Hz, 1H), 6.80 (d, J¼ 3.6 Hz, 1H); MS (ESI) m/z 252 [M þ H]þ.
4.1.4. 5-(4-Fluorophenyl)furan-2-carbaldehyde (5d)
Starting from 3d (100mg, 0.45mmol) and 4 (88mg, 0.63mmol),
the title compound was prepared following the procedure
described for the synthesis of compound 5a (Method A). The crude
product was puriﬁed by ﬂash chromatography on silica gel (5%
EtOAc in petroleum ether) to give 5d as a yellow oil (70mg, 82%).1H
NMR (400MHz, CDCl3) d 9.59 (s, 1H), 7.78e7.72 (m, 2H), 7.27 (d,
J¼ 3.5 Hz, 1H), 7.14e7.04 (m, 2H), 6.74 (d, J¼ 3.4 Hz, 1H); MS (ESI)
m/z 191 [M þ H]þ, 213 [M þ Na]þ.
4.1.5. 5-(2-Methoxyphenyl)furan-2-carbaldehyde (5e)
Starting from 3e (160mg, 0.75mmol) and 4 (147mg,
1.05mmol), the title compound was prepared following theprocedure described for the synthesis of compound 5a (Method A).
The crude product was puriﬁed by ﬂash chromatography on silica
gel (5% EtOAc in petroleum ether) to give 5e as a yellow oil (50mg,
33%). 1H NMR (300MHz, CDCl3) d 9.63 (s, 1H), 8.03 (d, J¼ 5.2 Hz,
1H), 7.40e7.34 (m, 1H), 7.32 (dd, J¼ 3.8, 1.2 Hz, 1H), 7.12 (dd, J¼ 3.7,
1.1 Hz, 1H), 7.08e6.96 (m, 2H), 3.93 (s, 3H); MS (ESI) m/z 225
[M þ Na]þ.
4.1.5.1. 5-(2-Benzyloxyphenyl)furan-2-carbaldehyde (5f).
Starting from 3f (250mg, 0.80mmol) and 4 (158mg, 1.12mmol),
the title compound was prepared following the procedure
described for the synthesis of compound 5a (Method A). The crude
product was puriﬁed by ﬂash chromatography on silica gel (5%
EtOAc in petroleum ether) to give 5f as a yellow oil (122mg, 55%).
1H NMR (300MHz, CDCl3) d 9.58 (s, 1H), 8.05 (d, J¼ 7.8 Hz, 1H),
7.47e7.35 (m, 5H), 7.35e7.26 (m, 1H), 7.26 (d, J¼ 1.1 Hz, 1H),
7.08e7.01 (m, 3H), 5.14 (s, 2H); MS (ESI) m/z 301 [M þ Na]þ.
4.1.5.2. 5-(2-Hydroxyphenyl)furan-2-carbaldehyde (6). To a solu-
tion of 5f (122mg, 0.43mmol), in dry dichloromethane (DCM)
(7mL), boron trichloride (395 mL, 4.38mmol) was added at 78 C.
After 3 h, the mixture warmed to 25 C and the solvent was
removed in vacuo. The crude product was puriﬁed by ﬂash chro-
matography on silica gel (2% MeOH in DCM) to give 6 as yellow oil
(97mg, 55%). 1H NMR (75MHz, CDCl3) d 9.63 (s, 1H), 7.60 (d,
J¼ 6.5 Hz, 1H), 7.26 (d, J¼ 1.1 Hz, 1H), 7.13e7.08 (m, 1H), 6.92e6.84
(m, 2H), 6.76 (d, J¼ 3.3 Hz, 1H), 6.28 (d, J¼ 2.0 Hz, 1H); MS (ESI)m/z
189 [M þ H]þ.
4.1.6. 1-(5-(4-Bromo-2-chlorophenyl)furan-2-yl)-N-(piperidin-4-
ylmethyl)methanamine (1)
A solution of 5a (90mg, 0.31mmol) and 7 (67mg, 0.31mmol) in
MeOH (10mL), was heated under reﬂux for 12 h. After this time, the
reaction was cooled to 0 C and sodium borohydride (12mg,
0.31mmol) was added. After 1 h, the solvent was removed in vacuo,
EtOAc was added (10mL) and the organic phase was washed with a
saturated solution of ammonium chloride (1 3mL), dried over
sodium sulfate, ﬁltered and evaporated in vacuo. The crude product
was puriﬁed by ﬂash chromatography on silica gel (2% MeOH in
DCM) to give the N-Boc protected intermediate as yellow oil
(90mg, 60%). 1H NMR (300MHz, CDCl3) d 7.65 (d, J¼ 8.6 Hz, 1H),
7.53 (d, J¼ 1.9 Hz, 1H), 7.37 (dd, J¼ 8.5, 1.9 Hz, 1H), 7.02 (d,
J¼ 3.3 Hz, 1H), 6.27 (d, J¼ 3.3 Hz, 1H), 4.06 (d, J¼ 9.6 Hz, 2H), 3.79
(s, 2H), 2.66 (dd, J¼ 22.1, 9.9 Hz, 2H), 2.50 (d, J¼ 6.6 Hz, 2H), 1.67 (d,
J¼ 13.0 Hz, 2H), 1.61e1.49 (m, 1H), 1.47e1.36 (m, 9H), 1.08 (d,
J¼ 16.2, Hz, 2H); 13C NMR (75MHz, CDCl3) d 155.1, 152.9, 148.9,
133.4, 130.6, 130.3, 128.6, 128.4, 120.6, 112.3, 111.0, 79.5, 59.6, 57.6,
50.8, 34.7, 30.6, 28.7; MS (ESI) m/z 506 [M þ Na]þ. A solution 1 N
Fig. 5. A. Inhibitory activity against PfPMT by compounds 1,24,25,48 at 100 mM; B. PfPMT inhibitory activity (IC50, mM) of 25. All assays were performed as described in the methods
section with values shown as mean ± standard deviation (n¼ 3).
Fig. 6. Putative mode of interaction of compound 25 (yellow sticks) within the active site of PfPMT (deep teal cartoon; PDB ID 3UJ8). H-bonds are represented by black dotted lines.
The picture was generated by PyMOL (The PyMOL Molecular Graphics System, v1.8.0; Schrodinger, LLC, New York, 2015). (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the Web version of this article.)
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MeOH (4.64mL). This solution (540 mL, 0.54mmol) was added to
the above described intermediate (90mg, 0.18mmol) at 0 C and
themixture kept at 25 C for 4 h. The solvent was removed in vacuo,
a saturated solution of sodium bicarbonate was added and the
organic phase was extracted with EtOAc (3 4mL), dried over so-
dium sulfate, ﬁltered and evaporated in vacuo, giving the product 1
as yellow oil without further puriﬁcation (68mg, 100%). 1H NMR
(300MHz, CD3OD) d 7.88 (d, J¼ 8.5 Hz, 1H), 7.72 (d, J¼ 1.8 Hz, 1H),
7.58 (d, J¼ 6.8 Hz,1H), 7.19 (d, J¼ 3.3 Hz,1H), 6.85 (d, J¼ 3.3 Hz,1H),
4.42 (s, 2H), 3.44 (d, J¼ 12.7 Hz, 2H), 3.05 (dd, J¼ 17.7, 9.1 Hz, 2H),
2.17 (brs, 1H), 2.06 (d, J¼ 14.3 Hz, 2H), 1.55 (dd, J¼ 23.5, 11.6 Hz,2H); 13C NMR (75MHz, CD3OD) d 150.6, 147.1, 133.1, 130.8, 130.4,
129.2, 127.8, 121.4, 113.7, 112.37, 51.9, 43.9, 43.4, 31.9, 26.4. MS (ESI)
m/z 383 [M þ H]þ. Anal. (C17H20BrClN2O) C, H, N.
4.1.7. 1-(5-Phenylfuran-2-yl)-N-piperidin-4-ylmethyl-
methanamine (8)
Starting from 5b (30mg, 0.17mmol) and 7 (36mg, 0.17mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1 to afford 8 as yellow oil (29mg, 64%
over two steps). 1H NMR (400MHz, CDCl3) d 7.61 (d, J¼ 7.6 Hz, 2H),
7.34 (t, J¼ 7.6 Hz, 2H), 7.22 (dd, J¼ 12.1, 4.9 Hz, 1H), 6.55 (d,
J¼ 3.1 Hz, 1H), 6.23 (d, J¼ 3.1 Hz, 1H), 3.80 (s, 2H), 3.33 (d,
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(d, J¼ 13.5 Hz, 2H), 1.64 (d, J¼ 3.0 Hz, 1H), 1.54e1.40 (m, 2H); 13C
NMR (75MHz, CDCl3) d 154.0, 153.3, 131.1, 128.8, 127.3, 123.8, 109.2,
105.8, 55.7, 46.8, 36.8; MS (ESI)m/z 271 [MþH]þ. Anal. (C17H22N2O)
C, H, N.
4.1.8. 1-(5-(4-Bromophenyl)furan-2-yl)-N-(piperidin-4-ylmethyl)
methanamine (9)
Starting from 5c (64mg, 0.25mmol) and 7 (53mg, 0.17mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 9 as yellow oil (38mg, 64% over two steps). 1H NMR
(400MHz, CD3OD) d 7.59 (d, J¼ 8.5 Hz, 2H), 7.48 (d, J¼ 8.6 Hz, 2H),
6.78 (d, J¼ 3.3 Hz, 1H), 6.68 (d, J¼ 3.2 Hz, 1H), 4.34 (s, 2H), 3.38 (d,
J¼ 12.5 Hz, 2H), 3.02 (d, J¼ 6.8 Hz, 2H), 2.95 (d, J¼ 11.4 Hz, 2H), 2.11
(brs, 1H), 2.01 (d, J¼ 13.6 Hz, 2H), 1.51 (dd, J¼ 23.4, 11.3 Hz, 2H); 13C
NMR (75MHz, CD3OD) d 154.8, 144.8, 131.8, 129.3, 125.6, 121.6,
114.9, 106.8, 51.3, 43.7, 43.2, 31.3, 26.2; MS (ESI) m/z 349 [M þ H]þ.
Anal. (C17H21BrN2O) C, H, N.
4.1.9. 1-(5-(4-Fluorophenyl)furan-2-yl)-N-(piperidin-4-ylmethyl)
methanamine (10)
Starting from 5d (32mg, 0.17mmol) and 7 (36mg, 0.17mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 10 as yellow oil (37mg, 75% over two steps). 1H NMR
(400MHz, CD3OD) d 7.76 (d, J¼ 5.6 Hz, 2H), 7.16 (d, J¼ 8.7 Hz, 2H),
6.79 (d, J¼ 3.2 Hz, 1H), 6.74 (d, J¼ 3.2 Hz, 1H), 4.40 (s, 2H), 3.44 (d,
J¼ 12.1 Hz, 2H), 3.07 (d, J¼ 6.6 Hz, 2H), 3.00 (d, J¼ 13.2 Hz, 2H), 2.15
(brs, 1H), 2.04 (d, J¼ 12.3 Hz, 2H), 1.54 (dd, J¼ 23.4, 11.3 Hz, 2H); 13C
NMR (75MHz, CD3OD) d 164.4, 161.1, 155.0, 144.5, 144.5, 126.8,
126.7, 126.0, 125.9, 115.7, 115.4, 114.9, 105.9, 105.9, 51.3, 43.7, 43.2,
31.3, 26.2; MS (ESI) m/z 289 [M þ H]þ. Anal. (C17H21FN2O) C, H, N.
4.1.10. 1-(5-(2-Methoxyphenyl)furan-2-yl)-N-(piperidin-4-
ylmethyl)methanamine (11)
Starting from 5e (50mg, 0.25mmol) and 7 (53mg, 0.25mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 11 as yellow oil (49mg, 65% over two steps). 1H NMR
(300MHz, CD3OD) d 7.81 (d, J¼ 7.8 Hz, 1H), 7.22 (t, J¼ 7.8 Hz, 1H),
7.07e6.94 (m, 2H), 6.84 (d, J¼ 3.2 Hz, 1H), 6.33 (d, J¼ 2.6 Hz, 1H),
3.92 (s, 3H), 3.80 (s, 2H), 3.05 (d, J¼ 12.4 Hz, 2H), 2.61 (t, J¼ 12.5 Hz,
2H), 2.50 (d, J¼ 6.6 Hz, 2H), 1.77 (d, J¼ 13.0 Hz, 2H), 1.65 (m, 1H),
1.21e1.08 (m, 2H); MS (ESI)m/z 301 [Mþ H]þ, 323 [Mþ Na]þ. Anal.
(C18H24N2O2) C, H, N.
4.1.11. 1-(5-(2-Hydroxyphenyl)furan-2-yl)-N-(piperidin-4-
ylmethyl)methanamine (12)
Starting from 6 (80mg, 0.42mmol) and 7 (90mg, 0.42mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 16 as yellow oil (72mg, 60% over two steps). 1H NMR
(300MHz, CD3OD) d 7.75e7.71 (m, 1H), 7.09e7.02 (m, 1H),
6.91e6.81 (m, 3H), 6.32 (d, J¼ 2.7 Hz, 1H), 3.78 (s, 2H), 3.00 (d,
J¼ 12.4 Hz, 2H), 2.57 (d, J¼ 12.2 Hz, 2H), 2.48 (d, J¼ 6.7 Hz, 2H),1.72
(d, J¼ 13.2 Hz, 2H), 1.66e1.55 (m, 1H), 1.21e1.02 (m, 2H); MS (ESI)
m/z 287 [M þ H]þ. Anal. (C17H22N2O2) C, H, N.
4.1.12. tert-Butyl 4-formylpiperidine-1-carboxylate (14)
To a solution of (methoxymethyl)triphenylphosphoniumchloride (6.3 g, 18.3mmol) in dry tetrahydrofuran (THF, 20mL),
sodium bis(trimethylsilyl)amide (1M in dry THF, 45mmol) was
added dropwise at 0 C. After 1 h, a solution of 13 (2.8 g, 14.1mmol)
in dry THF (20mL)was slowly added at 0 C and themixture kept at
25 C for 12 h. The solvent was removed in vacuo, H2O and EtOAc
were added and the organic phase was separated, washed with an
aqueous solution of HCl 1 N (1 5mL) and with a saturated solu-
tion of sodium bicarbonate (1 5mL), dried over sodium sulfate,
ﬁltered and evaporated in vacuo. The crude reaction mixture was
puriﬁed by ﬂash chromatography on silica gel (2% EtOAc in petro-
leum ether) to give the enolether intermediate tert-butyl 4-
(methoxymethylene)piperidine-1-carboxylate as yellow oil (1.28 g,
40%). 1H NMR (300MHz, CDCl3) d 5.81 (s, 1H), 3.51 (s, 3H), 3.33 (t,
J¼ 6.3 Hz, 4H), 2.20 (t, J¼ 6.0 Hz, 2H), 1.96 (t, J¼ 6.0 Hz, 2H), 1.42 (s,
9H); MS (ESI) m/z 250 [M þ Na]þ. To a solution of the above-
described compound (807mg, 3.6mmol) in CH3CN (20mL), cerium
chloride (530mg, 1.4mmol) and sodium iodide (160mg, 1.1mmol)
were added. The reaction mixturewas heated under reﬂux for 12 h.
The solvent was removed in vacuo and the crude product was pu-
riﬁed by ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH,
in DCM) to give 14 as yellow oil (667mg, 87%). 1H NMR (300MHz,
CDCl3) d 9.57 (s, 1H), 3.88 (d, J¼ 13.3 Hz, 2H), 2.84 (t, J¼ 10.9 Hz,
2H), 2.39e2.28 (m,1H), 1.80 (d, J¼ 13.5, 2H), 1.49e1.41 (m, 2H), 1.36
(s, 9H). MS (ESI) m/z 268 [M þ MeOH þ K]þ.
4.1.13. tert-Butyl 4-(azidomethyl)piperidine-1-carboxylate (15)
To a solution of 14 (660mg, 3.1mmol) in MeOH (10mL), sodium
borohydride (117mg, 3.1mmol) was added at 0 C and the mixture
kept at 25 C for 1 h. The solvent was removed in vacuo, EtOAc was
added (15mL) and the organic phase was washed with a saturated
solution of ammonium chloride (1 5mL), dried over sodium
sulfate, ﬁltered and evaporated in vacuo. The alcohol tert-butyl 4-
(hydroxymethyl)piperidine-1-carboxylate was obtained as yellow
oil without further puriﬁcation (666mg, 100%). 1H NMR (300MHz,
CDCl3) d 4.03e3.90 (d, J¼ 12.6 Hz, 2H), 3.31 (d, J¼ 6.2 Hz, 2H), 2.56
(t, J¼ 12.8 Hz, 2H),1.67e1.54 (m, 2H),1.54e1.42 (m,1H),1.32 (s, 9H),
1.07e0.90 (m, 2H); 13C NMR (75MHz, CDCl3) d 154.9, 79.3, 67.6,
67.0, 43.7, 38.8, 38.7, 37.7, 28.4; MS (ESI) m/z 238 [M þ Na]þ. To a
solution of the above-described alcohol (666 mg, 3.1 mmol) in dry
DCM (30 mL), triethylamine (2.6 mL, 18.6 mmol) and meth-
anesulfonyl chloride (959 mL, 12.4 mmol) were added dropwise at
0 C. The reaction mixture was kept at 25 C for 12 h. A saturated
solution of sodium bicarbonate (5 mL) was added and the organic
phase was extracted with DCM (3  10 mL), dried over sodium
sulfate, ﬁltered and evaporated in vacuo. The crude product was
puriﬁed by ﬂash chromatography on silica gel (2%MeOH in DCM) to
give mesylate intermediate as yellow oil (900mg, 99%). 1H NMR
(300MHz, CDCl3) d 3.98e3.73 (m, 2H), 2.97e2.84 (m, 2H), 2.79 (s,
3H), 2.48 (t, J¼ 13.1 Hz, 2H), 1.67 (br s, 1H), 1.50 (d, J¼ 13.2 Hz, 2H),
1.21 (s, 9H), 1.05e0.92 (m, 2H); 13C NMR (75MHz, CDCl3) d 154.8,
79.6, 73.7, 43.3, 37.3, 36.0, 31.8, 28.5, 28.3; MS (ESI) m/z 294
[MþH]þ. To a solution of the above compound (900mg, 3.1 mmol)
in dry N,N-dimethylformamide (DMF) (10mL), sodium azide
(400mg, 6.2mmol) was added at 0 C. The reaction was heated
under reﬂux at 90 C for 12 h. The solvent was removed in vacuo
and the product 15 was obtained as yellow oil without further
puriﬁcation (0.52 g, 70%). 1H NMR (300MHz, CDCl3) d 4.01 (d,
J¼ 12.1 Hz, 2H), 3.08 (d, J¼ 6.3 Hz, 2H), 2.57 (t, J¼ 12.8 Hz, 2H),
1.68e1.49 (m, 3H), 1.34 (s, 9H), 1.15e0.96 (m, 1H); 13C NMR
(75MHz, CDCl3) d 111.3, 79.7, 57.2, 43.4, 36.7, 29.8, 28.6; MS (ESI)m/
z 263 [M þ Na]þ.
4.1.14. tert-Butyl 4-(aminomethyl)piperidine-1-carboxylate (7)
To a solution of 15 (520mg, 2.1mmol) in MeOH (15mL), a cat-
alytic amount of palladium on carbon 10wt.% was added under
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hydrogen gas. The mixture was stirred at 25 C for 3 h. The sus-
pensionwas ﬁltered on paper and concentrated in vacuo giving 7 as
colorless oil without further puriﬁcation (427mg, 95%). 1H NMR
(300MHz, CDCl3) d 3.88 (d, J¼ 13.1 Hz, 2H), 2.50 (d, J¼ 17.4 Hz, 4H),
2.45e2.33 (m, 2H), 1.50 (d, J¼ 13.0 Hz, 2H), 1.38e1.27 (m, 1H), 1.27
(s, 9H), 0.90e0.45 (m, 2H); 13C NMR (75MHz, CDCl3) d 155.0, 79.3,
48.1, 43.4, 39.7, 29.9, 28.6; MS (ESI) m/z 215 [M þ H]þ.
4.1.15. 5-(4-Chloro-2-bromophenyl)furan-2-carbaldehyde (18b)
Starting from 16b (2.0 g, 9.7mmol) and 17 (802 mL, 9.7mmol),
the title compound was prepared following the procedure
described for the synthesis of compound 5a (Method B). The crude
product was puriﬁed by ﬂash chromatography on silica gel (5%
EtOAc in petroleum ether) to give 18b as an orange solid (2.5 g,
90%). mp (EtOAc/n-hexane)141e144 C; 1H NMR (300MHz, CDCl3)
d 9.69 (s, 1H), 7.89 (d, J¼ 8.5 Hz, 1H), 7.71 (d, J¼ 2.0 Hz, 1H), 7.40 (d,
J¼ 8.6, Hz, 1H), 7.35 (q, J¼ 3.8 Hz, 2H); 13C NMR (75MHz, CDCl3)
d 177.6, 154.6, 151.8, 133.7, 132.4, 130.7, 130.2, 126.8, 123.6, 123.0,
113.6. MS (ESI) m/z 308 [M þ Na]þ.
4.1.16. 5-(2-Chlorophenyl)furan-2-carbaldehyde (18c)
Starting from 16c (100mg, 0.78mmol) and 17 (65 mL,
0.78mmol), the title compound was prepared following the pro-
cedure described for the synthesis of compound 5a (Method B).
The crude product was puriﬁed by ﬂash chromatography on silica
gel (10% EtOAc in petroleum ether) to give 18c as a yellow solid
(112mg, 70%). mp (EtOAc/n-hexane) 68e72 C; 1H NMR (400MHz,
CDCl3) d 9.66 (s, 1H), 7.97 (d, J¼ 5.9 Hz, 1H), 7.44 (d, J¼ 6.5 Hz, 1H),
7.36e7.26 (m, 4H); MS (ESI) m/z 207 [M þ H]þ, 228 [M þ Na]þ.
4.1.17. 5-(4-(Triﬂuoromethyl)phenyl)furan-2-carbaldehyde (18d)
Starting from 16d (300mg, 1.86mmol) and furaldehyde 17
(154 mL,1.86mmol), the title compoundwas prepared following the
procedure described for the synthesis of compound 5a (Method B).
The crude product was puriﬁed by ﬂash chromatography on silica
gel (5% EtOAc in petroleum ether) to give 18d as yellow solid
(312mg, 70%). mp (EtOAc/n-hexane) 64e66 C; 1H NMR (300MHz,
CDCl3) d 9.65 (s, 1H), 7.85 (d, J¼ 8.6 Hz, 2H), 7.64 (d, J¼ 8.6 Hz, 2H),
7.30 (d, J¼ 3.8 Hz, 1H), 6.91 (d, J¼ 3.8 Hz, 1H); MS (ESI) m/z 263
[M þ Na]þ.
4.1.18. 4-(5-Formylfuran-2-yl)benzonitrile (18e)
Starting from 16e (600mg, 5.1mmol) and furaldehyde 17
(421 mL,1.86mmol), the title compoundwas prepared following the
procedure described for the synthesis of compound 5a (Method B).
The crude product was puriﬁed by ﬂash chromatography on silica
gel (15% EtOAc in petroleum ether) to give 18e as brown solid
(753mg, 75%). mp (EtOAc/n-hexane) 145e150 C; 1H NMR
(300MHz, CDCl3) d 9.71 (s, 1H), 7.92 (d, J¼ 8.6 Hz, 2H), 7.76 (d,
J¼ 8.6 Hz, 2H), 7.34 (d, J¼ 3.4 Hz, 1H), 6.97 (d, J¼ 3.4 Hz, 1H); MS
(ESI) m/z 220 [M þ Na]þ.
4.1.19. 5-(4-Phenyl-2-chlorophenyl)furan-2-carbaldehyde (19a)
Triphenylphosphine (220mg, 0.84mmol) and palladium (II)
acetate (12mg, 0.05mmol) were dissolved in dry toluene (3mL)
under argon atmosphere. After 30min, a solution of 5a (300mg,
1.05mmol) in dry toluene (5mL) was added. After further 30min, a
solution of sodium carbonate (701mg, 6.6mmol) in H2O (3mL) and
powdered phenyl boronic acid (128mg, 1.05mmol) were added in
this order. Reaction was heated under reﬂux for 12 h. The solvent
was removed under vacuo. H2O (2mL) and EtOAc (8mL) were
added, the organic phase was separated, dried over sodium sulfate,
ﬁltered and evaporated in vacuo. The crude product was puriﬁed by
ﬂash chromatography on silica gel (5% EtOAc in petroleum ether) togive 19a as yellow oil (254mg, 85%). 1H NMR (300MHz, CDCl3)
d 9.69 (s, 1H), 8.08 (d, J¼ 1.5 Hz, 1H), 7.70 (d, J¼ 1.6 Hz,1H),
7.62e7.56 (m, 3H), 7.50e7.36 (m, 3H), 7.35 (d, J¼ 0.8 Hz, 2H); 13C
NMR (75MHz, CDCl3) d 177.6, 157.7, 151.5, 142.6, 140.0, 135.4, 131.1,
129.8, 129.4, 129.0 (2C), 127.5, 127.3, 126.4 (2C), 115.6, 112.3; MS
(ESI) m/z 305 [M þ Na]þ.4.1.20. 5-(2-Phenyl-4-chlorophenyl)furan-2-carbaldehyde (19b)
Starting from 18b (80mg, 0.28mmol) and phenylboronic acid
(35mg, 0.28mmol), the title compound was prepared following
the procedure reported for compound 19a. The crude product was
puriﬁed by ﬂash chromatography on silica gel (5% EtOAc in petro-
leum ether) to give 19b as yellow oil (50mg, 63%). 1H NMR
(300MHz, CDCl3) d 9.55 (s, 1H), 7.93 (d, J¼ 5.3 Hz, 1H), 7.44e7.40
(m, 5H), 7.33 (d, J¼ 2.7 Hz, 2H), 7.02 (d, J¼ 3.1 Hz, 1H), 5.62 (d,
J¼ 3.7 Hz, 1H); 13C NMR (75MHz, CDCl3) d 177.6, 157.7, 151.5, 142.6,
140.0, 135.4, 131.1, 129.8, 129.4, 129.0 (2C), 127.5, 127.4, 126.4, 120.4,
115.6, 112.3; MS (ESI) m/z 305 [M þ Na]þ.4.1.21. 1-(5-(2-Bromo-4-chlorophenyl)furan-2-yl)-N-(piperidin-4-
ylmethyl)methanamine (21)
Starting from 18b (50mg, 0.18mmol) and 7 (38mg, 0.18mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 21 as yellow oil (48mg, 70% over two steps). 1H NMR
(300MHz, CDCl3) d 7.65 (d, J¼ 1.2 Hz, 1H), 7.61 (s, 1H), 7.28 (d,
J¼ 2.2 Hz, 1H), 7.05 (s, 1H), 6.27 (s, 1H), 3.78 (s, 2H), 3.30 (d,
J¼ 11.1 Hz, 2H), 2.74 (t, J¼ 11.8 Hz, 2H), 2.53 (d, J¼ 5.2 Hz, 2H), 1.86
(d, J¼ 12.9 Hz, 2H), 1.61 (s, 1H), 1.48e1.30 (m, 2H); 13C NMR
(75MHz, CD3OD) d 153.7, 149.5, 133.1, 132.9, 129.8, 129.1, 127.5,
118.9, 111.5, 109.2, 54.3, 45.3, 44.7, 34.9, 29.2; MS (ESI) m/z 383
[M þ H]þ. Anal. (C17H20BrClN2O) C, H, N.4.1.22. 1-(5-(2-Chlorophenyl)furan-2-yl)-N-(piperidin-4-ylmethyl)
methanamine (22)
Starting from 18c (45mg, 0.22mmol) and 7 (47mg, 0.22mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 22 as yellow oil (48mg, 68% over two steps). 1H NMR
(300MHz, CD3OD) d 7.91 (dd, J¼ 7.8, 1.7 Hz, 1H), 7.51e7.47 (m, 1H),
7.41e7.26 (m, 2H), 7.12 (d, J¼ 3.5 Hz, 1H), 6.75 (d, J¼ 3.5 Hz, 1H),
4.32 (s, 2H), 3.40 (d, J¼ 2.4 Hz, 2H), 3.30 (dt, J¼ 2.3, 1.6 Hz, 2H),
3.04e2.94 (m, 2H), 2.15e2.07 (m, 1H), 2.02 (d, J¼ 14.3 Hz, 2H), 1.52
(td, J¼ 14.7, 4.0 Hz, 2H); 13C NMR (75MHz, CD3OD) d 151.7, 146.3,
130.7, 130.2, 129.0, 128.6, 128.2, 127.1, 113.8, 111.8, 51.7, 43.9, 43.3,
31.7, 26.4; MS (ESI) m/z 305 [M þ H]þ. Anal. (C17H21ClN2O) C, H, N.4.1.23. 1-(5-(4-Triﬂuoromethylphenyl)furan-2-yl)-N-(piperidin-4-
ylmethyl)methanamine (23)
Starting from 18d (100mg, 0.41mmol) and 7 (89mg,
0.41mmol), the N-Boc-protected intermediate was prepared and
deprotected as described for the synthesis of 1. The crude product
was puriﬁed by ﬂash chromatography on silica gel (10% MeOH, 1%
NH4OH, in DCM) to give 23 as yellow oil (90mg, 65% over two
steps). 1H NMR (300MHz, CD3OD) d 7.86 (d, J¼ 8.1 Hz, 2H), 7.66 (d,
J¼ 7.6 Hz, 2H), 6.89 (d, J¼ 3.3 Hz, 1H), 6.42 (d, J¼ 3.3 Hz, 1H), 3.83
(s, 2H), 3.16 (d, J¼ 11.7 Hz, 2H), 2.72 (t, J¼ 12.4 Hz, 2H), 2.53 (d,
J¼ 6.3 Hz, 2H), 1.85 (d, J¼ 14.0 Hz, 2H), 1.70 (brs, 1H), 1.28e1.15 (m,
2H); 13C NMR (75MHz, CD3OD) d 154.3, 151.6, 134.2, 128.5, 128.1,
125.4, 125.3, 125.3, 125.2, 123.3, 109.7, 107.8, 54.6, 45.3, 45.1, 35.4,
30.0; MS (ESI) m/z 338 [M þ H]þ. Anal. (C18H21F3N2O) C, H, N.
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methanamine (24)
Starting from 18e (51mg, 0.26mmol) and 7 (55mg, 0.41mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 24 as yellow oil (51mg, 67% over two steps). 1H NMR
(300MHz, CD3OD) d 7.88 (d, J¼ 8.6 Hz, 2H), 7.72 (d, J¼ 8.6 Hz, 2H),
7.03 (d, J¼ 3.5 Hz, 1H), 6.77 (d, J¼ 3.5 Hz, 1H), 4.41 (s, 2H),
3.47e3.37 (m, 2H), 3.08 (t, J¼ 7.7 Hz, 2H), 3.02e2.93 (m, 2H), 2.14
(brs, 1H), 2.08e2.00 (m, 2H), 1.51 (dd, J¼ 18.7, 8.6 Hz, 2H); 13C NMR
(75MHz, CD3OD) d 153.7, 146.3, 134.2, 132.6, 131.9, 124.4, 118.5,
115.15, 110.6, 109.4, 51.4, 43.6, 43.2, 31.3, 26.2; MS (ESI) m/z 296
[M þ H]þ. Anal. (C18H21N3O) C, H, N.
4.1.25. 1-(5-(2-Phenyl-4-chlorophenyl)furan-2-yl)-N-(piperidin-4-
ylmethyl)methanamine (25)
Starting from 19b (50mg, 0.17mmol) and 7 (38mg, 0.17mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 25 as yellow oil (52mg, 80% over two steps). 1H NMR
(300MHz, CD3OD) d 7.76 (d, J¼ 8.5 Hz, 1H), 7.43e7.35 (m, 4H),
7.27e7.21 (m, 3H), 6.10 (d, J¼ 3.1 Hz, 1H), 5.60 (d, J¼ 3.3 Hz, 1H),
3.63 (s, 2H), 3.05 (d, J¼ 12.4 Hz, 2H), 2.60 (t, J¼ 11.7 Hz, 2H), 2.39 (d,
J¼ 6.7 Hz, 2H), 1.72 (d, J¼ 13.0 Hz, 2H), 1.64e1.53 (m,1H), 1.20e1.04
(m, 2H); 13C NMR (75MHz, CD3OD) d 171.8, 152.7, 151.4, 141.1, 141.1,
132.7, 130.3, 128.7, 128.4, 128.2, 127.6, 127.5, 110.0, 109.2, 53.7, 45.3,
44.0, 33.9, 27.4; MS (ESI)m/z 381 [Mþ H]þ. Anal. for (C23H25ClN2O)
C, H, N.
4.1.26. 1-(5-(4-Phenyl-2-chlorophenyl)furan-2-yl)-N-(piperidin-4-
ylmethyl)methanamine (26)
Starting from 19a (50mg, 0.17mmol) and 7 (38mg, 0.17mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on alumina gel (2% MeOH, 0.5% NH4OH, in
DCM) to give 26 as yellow oil (33mg, 51% over two steps). 1H NMR
(300MHz, CD3OD) d 7.97 (d, J¼ 8.3 Hz, 1H), 7.72 (d, J¼ 1.9 Hz, 1H),
7.68e7.60 (m, 3H), 7.54e7.34 (m, 3H), 7.11 (d, J¼ 3.3 Hz,1H), 6.44 (d,
J¼ 3.3 Hz, 1H), 3.84 (s, 2H), 3.06 (d, J¼ 12.2 Hz, 2H), 2.61 (t,
J¼ 11.6 Hz, 2H), 2.52 (d, J¼ 6.9 Hz, 2H), 1.78 (d, J¼ 13.6 Hz, 2H), 1.66
(brs, 1H), 1.25e1.08 (m, 2H); 13C NMR (75MHz, CDCl3) d 154.3,
149.4, 140.9, 139.4, 133.4, 130.4, 130.3, 129.3, 129.1, 128.8, 128.2,
128.1, 127.1, 125.6, 112.0, 109.4, 55.7, 46.8, 46.7, 36.8, 31.6; MS (ESI)
m/z 381 [M þ H]þ. Anal. for (C23H25ClN2O) C, H, N.
4.1.27. 5-(4-Bromo-2-chlorophenyl)thiophene-2-carbaldehyde
(28a)
Starting from 16a (300mg, 1.5mmol) and 27 (135 mL, 1.5mmol),
the title compound was prepared following the procedure
described for the synthesis of compound 5a (Method B). The crude
product was puriﬁed by ﬂash chromatography on silica gel (10%
EtOAc in petroleum ether) to give 28a as yellow oil (360mg, 80%).
1H NMR (300MHz, CDCl3) d 9.93 (s, 1H), 7.75 (d, J¼ 3.9 Hz, 1H), 7.72
(d, J¼ 2.0 Hz,1H), 7.41 (s, 1H), 7.38e7.35 (m, 2H); 13C NMR (75MHz,
CDCl3) d 183.1, 148.7, 144.2, 136.3, 133.5, 133.5, 132.4, 131.1, 130.7,
129.1, 123.5; MS (ESI) m/z 302 [M þ H]þ.
4.1.28. 5-(2-Bromo-4-chlorophenyl)thiophene-2-carbaldehyde
(28b)
Starting from 16b (200mg, 0.97mmol) and 27 (87 mL,
0.97mmol), the title compound was prepared following the pro-
cedure described for the synthesis of compound 5a (Method B).
The crude product was puriﬁed by ﬂash chromatography on silicagel (10% EtOAc in petroleum ether) to give 28b as yellow oil
(227mg, 78%). 1H NMR (300MHz, CDCl3) d 9.93 (s, 1H), 7.75 (d,
J¼ 3.9 Hz, 1H), 7.72 (d, J¼ 2.0 Hz, 1H), 7.41 (s, 1H), 7.38e7.35 (m,
2H). 13C NMR: (75MHz, CDCl3) d 183.1, 148.7, 144.2, 136.3, 133.5,
133.5, 132.4, 131.1, 130.7, 129.1, 123.5. MS (ESI) m/z 302 [M þ H]þ.
4.1.29. 1-(5-(4-Bromo-2-chlorophenyl)thiophen-2-yl)-N-
(piperidin-4-ylmethyl)methanamine (29)
Starting from 28a (88mg, 0.4mmol) and 7 (85mg, 0.4mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 29 as yellow oil (115mg, 72% over two steps). 1H NMR
(300MHz, CDCl3) d 7.62 (s, 1H), 7.38 (d, J¼ 1.6 Hz, 1H), 7.26 (d,
J¼ 0.9 Hz, 1H), 7.20 (d, J¼ 2.4 Hz, 1H), 6.90 (d, J¼ 2.7 Hz, 1H), 3.98
(s, 2H), 3.08 (d, J¼ 12.2 Hz, 2H), 2.57 (d, J¼ 6.5 Hz, 2H), 1.74 (m, 4H),
1.61 (brs, 2H), 1.29e1.07 (m, 3H); 13C NMR (75MHz, CDCl3) d 207.2,
146.4, 137.9, 133.2, 132.6, 132.3, 130.3, 127.8, 125.0, 121.4, 55.6, 49.0,
46.3, 36.6, 31.1; MS (ESI)m/z 400 [MþH]þ. Anal. (C17H20BrClN2S) C,
H, N.
4.1.30. 1-(5-(2-Bromo-4-chlorophenyl)thiophen-2-yl)-N-
(piperidin-4-ylmethyl)methanamine (30)
Starting from 28b (48mg, 0.2mmol) and 7 (43mg, 0.2mmol),
theN-Boc-protected intermediatewas prepared and deprotected as
described for the synthesis of 1. The crude product was puriﬁed by
ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH, in DCM)
to give 30 as yellow oil (50mg, 63% over two steps). 1H NMR
(300MHz, CD3OD) d 7.73 (s, 1H), 7.46 (d, J¼ 8.4 Hz, 1H), 7.40e7.37
(m, 1H), 7.14 (d, J¼ 1.5 Hz, 1H), 6.98 (d, J¼ 2.7 Hz, 1H), 3.95 (s, 2H),
3.06 (d, J¼ 12.8 Hz, 2H), 2.62 (t, J¼ 13.3, Hz, 2H), 2.51 (d, J¼ 6.6 Hz,
2H), 1.78 (d, J¼ 13.2 Hz, 2H), 1.65 (m, 1H), 1.28e1.08 (m, 2H); 13C
NMR (75MHz, CDCl3) d 207.2, 146.4, 137.9, 133.2, 132.6, 132.29,
130.3, 127.8, 125.0, 121.4, 55.6, 49.0, 46.3, 36.6, 31.1; MS (ESI) m/z
400 [M þ H]þ. Anal. (C17H20BrClN2S) C, H, N.
4.1.31. 1-(5-Bromobenzothiophen-2-yl)-N-(piperidin-4-ylmethyl)
methanamine (32)
Starting from 31 (40mg, 0.21mmol), the N-Boc-protected in-
termediate was prepared and deprotected as described for the
synthesis of 1. The crude product was puriﬁed by ﬂash chroma-
tography on silica gel (10% MeOH, 1% NH4OH, in DCM) to give 32 as
yellow oil (41mg, 60% over two steps). 1H NMR (300MHz, CD3OD)
d 7.97 (s, 1H), 7.61 (d, J¼ 8.5 Hz, 1H), 7.41 (d, J¼ 4.2, Hz, 1H), 7.20 (s,
1H), 4.01 (s, 2H), 3.03 (d, J¼ 12.4 Hz, 2H), 2.58 (t, J¼ 12.4, Hz, 2H),
2.49 (d, J¼ 6.7 Hz, 2H), 1.75 (d, J¼ 13.2 Hz, 2H), 1.71e1.56 (m, 1H),
1.13 (m, 2H); 13C NMR (75MHz, CD3OD) d 145.9, 141.6, 138.9, 127.4,
124.5, 124.3, 121.5, 117.3, 54.8, 45.4, 35.9, 30.4; MS (ESI) m/z 362
[M þ Na]þ. Anal. (C15H19BrN2S) C, H, N.
4.1.32. 4-Benzyl-3-(4-chlorophenyl)-4H-1,2,4-triazole (34)
To a solution of 33 (239.0mg, 0.95mmol) in MeCN (10mL),
DMF-DMA (128 mL, 0.95mmol) was added. The reactionwas heated
to 50 C for 1 h. After this time, benzylamine (101 mL, 0.85mmol)
and acetic acid (2mL) were added and reaction was heated at
120 C for 12 h. The solvent was removed under vacuo. The crude
product was puriﬁed by ﬂash chromatography on silica gel (2%
MeOH in EtOAc) to give 34 (198mg, 60%) as yellow oil. 1H NMR
(300MHz, CDCl3) d 8.19 (s, 1H), 7.46 (dd, J¼ 8.5, 2.1 Hz, 2H),
7.41e7.33 (m, 2H), 7.30e7.23 (m, 3H), 7.06e6.96 (m, 1H), 5.17 (s,
2H); MS (ESI) m/z 350 [M þ H]þ.
4.1.33. (4-Benzyl-5-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl)
methanol (35)
A solution of 34 (100mg, 0.29) in formaldehyde (aq. sol. 37%,
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under vacuo. The crude product was puriﬁed by ﬂash chromatog-
raphy on silica gel (2% MeOH in EtOAc) to give 35 as yellow oil. 1H
NMR (300MHz, CD3OD) d 7.55e7.44 (m, 4H), 7.32e7.26 (m, 2H),
7.03e6.97 (m, 2H), 5.45 (s, 2H), 4.81 (d, J¼ 1.2 Hz, 2H). (43mg, 50%).
MS (ESI) m/z 300 [M þ H]þ.
4.1.34. 4-Benzyl-3-(chloromethyl)-5-(4-chlorophenyl)-4H-1,2,4-
triazole (36a)
To a solution of 35 (40mg, 0.13mmol) in dry DCM (4mL), pyr-
idine (12 mL, 0.14mmol) and thionyl chloride (13 mL, 0.16mmol)
were added at 0 C. After 3 h an aqueous solution of sodium bi-
carbonate was added and the organic phase was extracted with
DCM, dried over sodium sulfate, ﬁltered and evaporated in vacuo.
The crude product was puriﬁed by ﬂash chromatography on silica
gel (2% MeOH in DCM) to give 36a as yellow oil (20mg, 50%). 1H
NMR (300MHz, CD3OD) d 7.55e7.44 (m, 4H), 7.32e7.26 (m, 2H),
7.03e6.97 (m, 2H), 5.43 (s, 2H), 4.92 (s, 2H); MS (ESI) m/z 319
[M þ H]þ.
4.1.35. 2-(2-Bromo-4-chlorophenyl)-5-(chloromethyl)-1,3,4-
oxadiazole (36b)
To a solution of 33 (200mg, 0.8mmol) in phosphoryl chloride
(2mL), chloroacetic aid (76mg, 0.8mmol) was added. The reaction
mixture was heated under reﬂux for 12 h. After this time the
mixture was cooled at 0 C, and an aqueous solution of sodium
bicarbonate (2mL) was slowly added. The organic phase was
extracted with EtOAc (3 5mL), dried over sodium sulfate, ﬁltered
and evaporated in vacuo. The crude product was puriﬁed by ﬂash
chromatography on silica gel (15% EtOAc in petroleum ether) to give
36b as yellow oil (49mg, 20%). 1H NMR (300MHz, CD3OD) d 8.04 (d,
J¼ 8.7 Hz, 1H), 7.94e7.89 (m, 1H), 7.60 (d, J¼ 8.0 Hz, 1H), 4.96 (s,
2H); 13C NMR (75MHz, CD3OD) d 139.13, 134.11, 132.61, 131.86,
130.09, 129.56, 128.36, 122.05, 32.49. MS (ESI) m/z 308 [M þ H]þ,
330 [M þ Na]þ.
4.1.36. 1-(5-(4-Chlorophenyl)-4H-1,2,4-triazol-3-yl)-N-(piperidin-
4-ylmethyl)methanamine (37)
To a solution of 36a (19mg, 0.060mmol) in dry MeCN (1mL), a
solution of 7 (20mg, 0.065mmol) in dry MeCN (2mL), potassium
carbonate (134mg, 0.97mmol) and a catalytic amount of potas-
sium iodide were slowly added. The reaction mixture was heated
under reﬂux for 1 h. After this time, the solvent was removed in
vacuo. H2O (1mL) and EtOAc (5mL) were added and the organic
phase was separated, dried over sodium sulfate, ﬁltered and
evaporated in vacuo. The crude product was puriﬁed by ﬂash
chromatography on silica gel (2% MeOH in DCM) to give 4-(4-
benzyl-5-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl)methylamino-N-
tert-butoxy carbonylpiperidine as colorless oil (21mg, 72%). 1H
NMR (300MHz, CD3OD) d 7.55e7.44 (m, 5H), 7.34e7.26 (m, 2H),
6.98 (d, J¼ 8.0 Hz, 2H), 5.47 (s, 2H), 4.02 (d, J¼ 13.4 Hz, 2H), 3.91 (s,
2H), 2.69 (s, 2H), 2.49 (s, 2H), 1.65 (d, J¼ 13.5 Hz, 2H), 1.61e1.50 (m,
1H), 1.44 (s, 9H), 1.11e0.94 (m, 2H); MS (ESI)m/z 497 [M þ H]þ, 535
[M þ K]þ. To a solution of the above product (20mg, 0.04mmol) in
DMSO (30 mL), a solution of potassium tert-butoxide (34mg,
0.30mmol) in dry THF (1mL) was added. The reaction environment
was saturated with oxygen. After 2 h an aqueous solution of
ammonium chloride (0.5mL) was added and the organic phasewas
extracted with EtOAc (3 3mL), dried over sodium sulfate, ﬁltered
and evaporated in vacuo. The crude product was puriﬁed by ﬂash
chromatography on silica gel (2% MeOH in DCM) to give [5-(4-
chlorophenyl)-4H-1,2,4-triazol-3-yl]methylamino-methyl-N-tert-
butoxy-carbonyl piperidine as yellow oil (14mg, 87%). 1H NMR
(300MHz, CD3OD) d 7.97 (d, J¼ 8.2 Hz, 2H), 7.48 (d, J¼ 7.9 Hz, 2H),
4.07 (d, J¼ 13.2, 2H), 3.96 (s, 2H), 2.77 (d, J¼ 12.0 Hz, 2H), 2.58 (d,J¼ 6.0 Hz, 2H), 1.76 (d, J¼ 12.4 Hz, 2H), 1.44 (s, 9H), 1.31e1.21 (m,
2H),1.15e1.04 (m,1H). MS (ESI)m/z 407 [MþH]þ. Starting from the
above compound (15mg, 0.03mmol) and HCl 1 N (120 mL,
0.12mmol), the title compound was deprotected as described for
the synthesis of 1. The crude product 37 was obtained as yellow oil
without further puriﬁcation (11mg, 84%). 1H NMR (300MHz,
CD3OD) d 8.03 (d, J¼ 8.2 Hz, 2H), 7.63 (d, J¼ 8.1 Hz, 2H), 4.62 (s, 2H),
3.46 (d, J¼ 12.1 Hz, 2H), 3.11 (t, J¼ 11.8 Hz, 2H), 2.83 (brs, 2H), 2.32
(brs, 1H), 2.14 (d, J¼ 11.9 Hz, 2H), 1.68 (d, J¼ 11.1 Hz, 2H); MS (ESI)
m/z 397 [M þ H]þ. Anal. (C15H20ClN5) C, H, N.
4.1.37. 1-(5-(2-Bromo-4-chlorophenyl)-1,3,4-oxadiazol-2-yl)-N-
(piperidin-4-ylmethyl)methan amine (38)
To a solution of 36b (12mg, 0.06mmol) in dry MeCN (1mL), a
solution of 7 (20mg, 0.065mmol) in dry MeCN (2mL), potassium
carbonate (134mg, 0.97mmol) and a catalytic amount of potas-
sium iodide were slowly added. The reaction mixture was heated
under reﬂux for 1 h. After this time, the solvent was removed in
vacuo. H2O (1mL) and EtOAc (5mL) were added and the organic
phase was separated, dried over sodium sulfate, ﬁltered and
evaporated in vacuo. The crude product was puriﬁed by ﬂash
chromatography on silica gel (2% MeOH in DCM) to give (5-(2-
bromo-4-chlorophenyl)-1,3,4-oxadiazol-2-yl)methylaminomethyl-
N-tert-butoxy carbonylpiperidine as yellow oil (25mg, 81%). 1H
NMR (300MHz, CD3OD) d 8.02 (d, J¼ 8.6 Hz, 1H), 7.89 (d, J¼ 5.0 Hz,
1H), 7.59 (dd, J¼ 8.5, 1.9 Hz,1H), 4.08 (d, J¼ 5.8 Hz, 2H), 4.03 (s, 2H),
2.74 (s, 2H), 2.57 (s, 2H), 1.74 (d, J¼ 13.9 Hz, 2H), 1.69e1.61 (m, 1H),
1,44 (s, 9H) 1.17e0.99 (m, 2H); MS (ESI) m/z 508 [M þ H]þ. Starting
from the above compound (20mg, 0.04mmol) and HCl 1 N (160 mL,
0.16mmol), the title compound was prepared following the pro-
cedure reported for compound 37. The solvent was removed in
vacuo. A saturated solution of sodium bicarbonate (1mL) was
added and the organic phase was extracted with EtOAc (3 3mL),
dried over sodium sulfate, ﬁltered and evaporated in vacuo. The
crude product was puriﬁed by ﬂash chromatography on silica gel
(10% MeOH, 1% NH4OH, in DCM) to give 38 as yellow oil (13mg,
82%). 1H NMR (300MHz, CD3OD) d 8.03 (d, J¼ 8.3 Hz, 1H), 7.91 (d,
J¼ 4.9, 1H), 7.59 (d, J¼ 8.5 Hz, 1H), 5.48 (s, 2H), 3.39 (d, J¼ 12.5 Hz,
2H), 3.32e3.27 (m, 2H), 2.97 (t, J¼ 12.4 Hz, 2H), 2.07e1.98 (m, 2H),
1.90e1.82 (m, 1H), 1.50e1.24 (m, 2H); MS (ESI) m/z 386 [M þ H]þ.
Anal. for (C15H18BrClN4O) C, H, N.
4.1.38. 2-Methyl-6-(4-(triﬂuoromethyl)phenyl)pyridine (41)
Triphenylphosphine (366mg, 1.4mmol) and palladium (II) ac-
etate (20mg, 0.1mmol) were dissolved in a mixture of dry DMF
(7mL) and H2O (3mL) under argon atmosphere. After 30min, 39
(198 mL, 1.7mmol) was added. After further 30min, potassium
carbonate (721mg, 5.2mmol) and powered 4-triﬂuoromethyl-
phenyl boronic acid 40 (331mg,1.7mmol) were added in this order.
The reaction mixture was heated at reﬂux for 12 h. The solvent was
removed under vacuo. H2O (2mL) and EtOAc (8mL) were added,
the organic phase was separated, dried over sodium sulfate, ﬁltered
and evaporated in vacuo. The crude product was puriﬁed by ﬂash
chromatography on silica gel (2% EtOAc in petroleum ether) to give
41 as white solid (336mg, 81%). 1H NMR (300MHz, CDCl3)
d 8.13e8.01 (d, J¼ 7,83 Hz, 2H), 7.67 (d, J¼ 8.6 Hz, 2H), 7.56 (t,
J¼ 7.73 Hz, 1H), 7.44 (d, J¼ 8.0 Hz, 1H), 7.07 (d, J¼ 7.8 Hz, 1H), 2.61
(s, 3H). MS (ESI) m/z 238 [M þ H]þ.
4.1.39. 2-(Bromomethyl)-6-(4-triﬂuoromethyl)phenylpyridine (42)
To a solution of 41 (336mg, 1.4mmol) in CCl4 (14mL), NBS
(904mg, 5.1mmol) and AIBN (98mg, 0.6mmol) were added
portion wise. The reaction was heated under reﬂux for 12 h. The
mixture was ﬁltered on paper and the ﬁltrate was concentrated
under vacuo. The crude product was puriﬁed by ﬂash
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42 as white solid (132mg, 30%). 1H NMR (300MHz, CDCl3) d 8.13 (d,
J¼ 8.00 Hz, 2H), 7.81 (t, J¼ 7.8 Hz, 1H), 7.73 (d, J¼ 8.12 Hz, 2H), 7.68
(d, J¼ 8.0 Hz, 1H), 7.46 (d, J¼ 7.6 Hz, 1H), 4.63 (s, 2H); MS (ESI) m/z
317 [M þ H]þ.
4.1.40. 1-(Piperidin-4-yl)-N-((6-(4-(triﬂuoromethyl)phenyl)
pyridin-2-yl)methyl)methanamine (43)
To a solution of 7 (66mg, 0.3mmol) in dry MeCN (1mL), was
slowly added a solution of 42 (49mg, 0.2mmol) in dry MeCN
(3mL) and powered potassium carbonate (171mg, 1.2mmol). After
12 h, the solvent was removed in vacuo. H2O (1mL) and EtOAc
(5mL) were added and the organic phase was washed with an
aqueous solution NaOH (1 N, 2mL) dried over sodium sulfate,
ﬁltered and evaporated in vacuo. The crude product was puriﬁed by
ﬂash chromatography on silica gel (2% MeOH in DCM) to give the
alkylation product 6-[4-(triﬂuoromethyl)phenyl-pyridin-2-yl]
methylamino-methyl-N-tert-butoxycarbonyl piperidine as color-
less oil. (18mg, 20%). 1H NMR: (300MHz, CD3OD) d 8.25 (d,
J¼ 8.1 Hz, 2H), 7.87e7.82 (m, 2H), 7.78 (d, J¼ 8.1 Hz, 2H), 7.40 (d,
J¼ 7.0 Hz, 1H), 4.06 (d, J¼ 13.5 Hz, 2H), 3.99 (s, 2H), 2.76 (t,
J¼ 12.7 Hz, 2H), 2.60 (d, J¼ 6.2 Hz, 2H), 1.78 (d, J¼ 12.0 Hz, 2H), 1.44
(s, 9H), 1.28 (s, 1H), 1.17e1.04 (m, 2H); MS (ESI) m/z 450 [M þ H]þ,
472 [M þ Na]þ. Starting from the above alkylation product (30mg,
0.06mmol) and HCl 1 N (240 mL, 0.24mmol), the title compound
was prepared following the deprotection procedure reported for
compound 1. The crude product was puriﬁed by ﬂash chromatog-
raphy on silica gel (10% MeOH, 1% NH4OH, in DCM) to give 43 as
yellow oil (20mg, 98%). 1H NMR (300MHz, CD3OD) d 8.25 (d,
J¼ 8.2 Hz, 2H), 7.87 (d, J¼ 7.3 Hz, 2H), 7.78 (d, J¼ 8.2 Hz, 2H), 7.40
(d, J¼ 7.1 Hz, 1H), 3.96 (s, 2H), 3.21 (d, J¼ 12.4 Hz, 2H), 2.78 (t,
J¼ 11.4 Hz, 2H), 2.58 (d, J¼ 6.6 Hz, 2H), 1.91 (d, J¼ 13.4 Hz, 2H), 1.80
(brs, 1H), 1.27 (m, 2H); 13C NMR (75MHz, CD3OD) d 162.1, 159.1,
155.3, 149.1, 143.0, 138.0, 130.8, 130.4, 127.4, 126.3, 125.5, 125.4,
119.5, 54.7, 54.1, 44.7, 35.0, 29.5, 29.0, 21.8, 17.6, 13.2, 7.1, 9.3. MS
(ESI) m/z 350 [M þ H]þ. Anal. f (C19H22F3N3) C, H, N.
4.1.41. N0-[(5-(4-Bromo-2-chlorophenyl)furan-2-yl)methyl]-N0,N0-
dimethylpropane-1,3-diamine (45)
To a solution of N1,N1-dimethylpropane-1,3-diamine 44 (22 mL,
0.17mmol) in dry DCM (2mL), was added a solution of aldehyde 5a
(45mg 0.16mmol) in dry DCM (5mL). After 1 h sodium triacetox-
yborohydride (51mg, 0.24mmol) was added at 0 C and the
mixture kept at 25 C for 12 h. After this time, sodium cyanobor-
ohydride (20mg, 0.32mmol) was added and the solution was
maintained at the same temperature for further 1 h. A saturated
solution of sodium bicarbonate (3mL) was added and the organic
phase was extracted with DCM (3 5mL), dried over sodium sul-
fate, ﬁltered and evaporated in vacuo. The crude product was pu-
riﬁed by ﬂash chromatography on silica gel (10% MeOH, 1% NH4OH,
in DCM) to give 45 as yellow oil (50mg, 85%). 1H NMR (300MHz,
CD3OD) d 7.82 (d, J¼ 6.1 Hz, 1H), 7.66 (s, 1H), 7.51 (d, J¼ 6.5 Hz, 1H),
7.09 (d, J¼ 3.2 Hz, 1H), 6.43 (d, J¼ 3.1 Hz, 1H), 3.83 (d, J¼ 2.1 Hz,
2H), 2.66 (t, J¼ 6.1 Hz, 2H), 2.43e2.36 (m, 2H), 2.26 (s, 6H),
1.74e1.70 (m, 2H); 13C NMR (75MHz, CD3OD) d 153.7, 148.7, 132.9,
130.3, 130.3, 128.8, 128.4, 120.4, 112.2, 109.8, 57.4, 46.9, 45.2, 44.1,
25.6; MS (ESI) m/z 394 [M þ Na]þ. Anal. (C16H20BrClN2O) C, H, N.
4.1.42. tert-Butyl [(5-(4-chloro-2-bromophenyl)furan-2-yl-
methyl]-3-dimethylaminopropyl carbamate (46)
Starting from 44 (65 mL, 0.5mmol) and 18b (130mg, 0.5mmol),
the title compound was prepared following the procedure reported
for compound 45. The crude product was puriﬁed by ﬂash chro-
matography on silica gel (10% MeOH, 1% NH4OH, in DCM) to give
N1-[(5-(4-chloro-2-bromophenyl)furan-2-yl-methyl]-N3,N3-dimethylpropane-1,3-diamine as yellow oil (92mg, 50%). 1H NMR
(300MHz, CD3OD) d 7.80 (d, J¼ 8.6 Hz, 1H), 7.68 (s, 1H), 7.43 (d,
J¼ 9.0 Hz,1H), 7.12 (d, J¼ 3.4 Hz,1H), 6.41 (d, J¼ 3.4 Hz,1H), 3.87 (s,
2H), 2.64 (t, J¼ 7.3 Hz, 2H), 2.41e2.26 (m, 2H), 2.22 (s, 6H), 1.80
(t J¼ 6.0 Hz, 2H); 13C NMR (75MHz, CD3OD) d 153.7, 148.7, 132.9,
130.3, 130.3, 128.8, 128.4, 120.4, 112.2, 109.8, 57.4, 46.86, 45.2, 44.1,
25.6; MS (ESI) m/z 394 [M þ Na]þ. To a solution of the above sec-
ondary amine (57mg, 0.2mmol) in dryMeOH (4mL), triethylamine
(63 mL, 0.5mmol) and di-tert-butyl dicarbonate (49mg, 0.2mmol)
were added. The reaction mixture was kept at 25 C for 4 h. After
this time, the solvent was removed in vacuo. H2O (2mL) was added
and the organic phase was extracted with EtOAc (3 3mL), dried
over sodium sulfate, ﬁltered and evaporated in vacuo. The crude
product was puriﬁed by ﬂash chromatography on silica gel (5%
MeOH in DCM) to give 46 as yellow oil (82mg, 87%). 1H NMR
(400MHz, CDCl3) d 7.65 (d, J¼ 8.5 Hz, 1H), 7.60 (s, 1H), 7.27 (d,
J¼ 8.5,1H), 7.06 (s, 1H), 6,28 (br s,1H), 4.42 (br s, 2H), 3.29 (br s, 2H),
2.19 (s, 6H), 1.67 (brs, 4H), 1.44 (s, 9H); MS (ESI) m/z 394 [M þ H]þ.4.1.43. 3-[(5-(4-Chloro-2-bromophenyl)furan-2-yl-methyl)amino]-
N,N,N-trimethylpropan-1-ammonium chloride (47)
To a solution of 46 (30mg, 0.1mmol) in dry acetone (2mL),
iodomethane (16 mL, 0.3mmol) was added. Reaction reﬂuxed for
72 h. The solvent was removed under vacuo. The crude product was
puriﬁed by ﬂash chromatography on alumina gel (33% MeCN in
DCM) to give (5-(2-bromo-4-chlorophenyl)furan-2-yl)methyl)
(tert-butoxycarbonyl)amino)-N,N,N-trimethylpropan-1-ammo-
nium iodide as yellow oil (29mg, 60%). 1H NMR (300MHz, CD3OD)
d 7.78e7.72 (m, 2H), 7.44 (d, J¼ 8.6 Hz, 1H), 7.12 (d, J¼ 3.4 Hz, 1H),
6.49 (d, J¼ 3.4 Hz, 1H), 4.54 (s, 2H), 3.43 (t, J¼ 6.9 Hz, 2H), 3.30 (s,
2H), 3.10 (s, 9H), 2.03 (br s, 2H), 1.50 (s, 9H). MS (ESI) m/z 485
[Mþ H]þ. To a solution of the above compound (10mg, 0.02mmol)
in MeOH (2mL), a solution of HCl 1 N (110 mL), prepared using
acetyl chloride (355 mL, 4.97mmol) in MeOH (4.64mL) was added
at 0 C. The reaction mixture was kept at 25 C for 4 h. The solvent
was removed under vacuo to give the 47 as colorless oil without
further puriﬁcation (7mg, 95%). 1H NMR (300MHz, CD3OD) d 7.89
(d, J¼ 7,01 1H), 7.48 (s, 1H), 7.21 (d, J¼ 3.4 Hz, 1H), 6.85 (d,
J¼ 3.4 Hz, 1H), 4.46 (s, 2H), 3.53 (br s, 4H), 3.20 (s, 9H), 2.28 (br s,
2H). (ESI) m/z 385 [M þ H]þ. Anal. for (C17H23BrCl2N2O) C, H, N.4.1.44. N-Benzyl-3-[(5-(4-chloro-2-bromophenyl)furan-2-yl-
methyl)amino]-N,N-dimethylpropan-1-ammonium chloride (48)
To a solution of 46 (30mg, 0.1mmol) in dry acetone (2mL),
benzyl bromide (38 mL, 0.3mmol) was added. The reaction mixture
was heated under reﬂux for 72 h. The solvent was removed under
vacuo. The crude product was puriﬁed by ﬂash chromatography on
silica gel (5% MeOH in DCM) to give the benzyldimethylammonium
bromide salt as yellow oil (32mg, 58%). 1H NMR (300MHz, CD3OD)
d 7.80e7.62 (m, 2H), 7.57e7.45 (m, 5H), 7.41 (d, J¼ 8.5 Hz, 1H), 7.09
(d, J¼ 3.5 Hz, 1H), 6.47 (d, J¼ 3.3 Hz, 1H), 4.54 (s, 2H), 4.49 (s, 2H),
3.46 (t, J¼ 6.7 Hz, 1H), 3.38e3.21 (m, 2H), 3.00 (s, 6H), 2.14 (t,
J¼ 9.0 Hz, 2H),1.49 (s, 9H); MS (ESI)m/z 562 [MþH]þ. To a solution
of the above compound (21mg, 0.04mmol) in MeOH (2mL), a
solution of HCl 1 N (222 mL), prepared using acetyl chloride (355 mL,
4.97mmol) in MeOH (4.64mL) was added at 0 C. The reaction
mixture was kept at 25 C for 4 h. The solvent was removed under
vacuo to give 48 as yellow oil without further puriﬁcation (17mg,
94%). 1H NMR (300MHz, CD3OD) d 7.90 (d, J¼ 7.7 Hz, 1H), 7.73 (s,
1H), 7.65e7.42 (m, 6H), 7,20 (s, 1H), 6.85 (s, 1H), 4.60 (s, 2H), 4.45 (s,
2H), 3.51 (br s, 2H), 3.22 (br s, 2H), 3.09 (s, 6H), 2.39 (br s, 2H); MS
(ESI) m/z 462 [M þ H]þ. Anal. (C23H27BrCl2N2O) C, H, N.
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Reference (1) and synthesized compounds were investigated for
their potential capability to behave as pan-assay interference
compounds (PAINS) by means of FAFDrugs4.0 [55,56]. Remarkably,
none of compounds contain sub-structural features that would
label them as “frequent hitters” in high throughput screens.
4.3. Antiplasmodial and gametocytocidal activity evaluation
4.3.1. Parasite growth of D10 and W2 strains
The CQ sensitive (D10) and the CQ resistant (W2) strains of
P. falciparum were maintained in vitro at 5% haematocrit (human
type A-positive red blood cells) in RPMI 1640 (EuroClone, Celbio)
mediumwith the addition of 1% AlbuMax (Invitrogen, Milan, Italy),
0.01% hypoxanthine, 20mM HEPES, and 2mM glutamine, at 37 C
in a standard gas mixture consisting of 1% O2, 5%CO2, and 94% N2
[39].
4.3.2. Antiplasmodial activity against D10 and W2 strains
Compounds were dissolved in DMSO and then diluted with
medium to achieve the required concentrations (ﬁnal DMSO con-
centration <1%, which is nontoxic to the parasite). Drugs were
placed in 96 well ﬂat-bottom microplates (COSTAR) and serial di-
lutions made. Asynchronous cultures with parasitemia of 1e1.5%
and 1% ﬁnal haematocrit were aliquoted into the plates and incu-
bated for 72 h at 37 C. Parasite growth was determined spectro-
photometrically (OD650) by measuring the activity of the parasite
lactate dehydrogenase (pLDH), according to a modiﬁed version of
Makler's method in control and drug-treated cultures [39]. Anti-
plasmodial activity is expressed as the 50%inhibitory concentra-
tions (IC50). Each IC50 value is the mean± standard deviation of at
least three separate experiments performed in duplicate.
4.3.3. Gametocytocidal activity against P. falciparum 3D7 strain
3D7elo1-pfs16-CBG99
Gametocytes were obtained from the transgenic P. falciparum
3D7 strain 3D7elo1-pfs16-CBG99 expressing the Pyrophorus pla-
giophthalamus CBG99 luciferase under the gametocyte speciﬁc
promoter pfs16. Late-stage gametocytes (stage IV-V, evaluated by
Giemsa staining) were exposed to compounds at day 8e10 after N-
acetylglucosamine (NAG) addition. For drug susceptibility assay,
compounds were prepared by serial dilution, in 96-well plate, in
complete medium. Epoxomicin or methylene blue were used as
reference drugs. After 72 h incubation, drug-treated gametocyte
samples at 2% haematocrit were transferred to 96-well black
microplates and D-luciferin (1mM in citrate buffer 0.1M, pH 5.5)
was added at a 1:1 vol ratio. After 10min incubation, gametocytes
viability was measured as luciferase activity using a Sinergy 4
(Biotek) microplate reader (500ms integration time). The IC50 was
extrapolated from the non-linear regression analysis of the
concentrationeresponse curve [23].
4.3.4. NF54
Asexual blood stage parasites were seeded at a density of 0.83%
in 1.5% haematocrit in RPMI1640 medium with 10% human serum
and combined with compounds serially diluted in DMSO and
RPMI1640 medium to reach a ﬁnal DMSO concentration of 0.1% in a
volume of 60 mL. Following a 72 h incubation at 37 C, 3% O2, 4% CO2,
30 mL of diluted Sybrgeen reagent was added according to the in-
structions of the manufacturer (Life Technologies) and ﬂuorescence
intensity was quantiﬁed using a Biotek Synergy 2 plate reader.
4.3.5. NF54 gametocytes
Gametocytes were obtained from a culture ﬂask inoculated with1% asexual blood stage parasites in 5% haematocrit in RPMI1640
medium with 10% human serum. From day 4 to day 9 post-inocu-
lation, cultures were treated with 50mM NAG to eliminate asexual
blood stage parasites. At day 11 post inoculation, gametocytes
(predominantly stage IV) were isolated by Percoll density gradient
centrifugation as described previously (PMID 25667405). Gameto-
cytes were seeded at a density of 5000 cells/well in a 384 well plate
and combined with compound diluted in DMSO and subsequently
in RPMI1640 medium to reach a ﬁnal DMSO concentration of 0.1%
in a volume of 60 mL RPMI1640 medium with 10% human serum.
Following a 72 h incubation at 37 C, 3% O2, 4% CO2, 30 mL of ONE-
Glo reagent (Promega) was added and luminescencewas quantiﬁed
using a Biotek Synergy 2 reader.
4.4. Liver-stage analysis
20'000 mCherry expressing P. berghei (ANKA strain) sporozoites
(PbmCherryhsp70, [57]) were used to infect mouse primary hepa-
tocytes grown on 96-well plate (isolated as published in Prado et al.
[58]). 2 hpi the cells were exposed to different concentrations of 25,
as control DMSO (equal to the highest concentration of 25) was
used. Medium/Drug was renewed at 24 hpi. At 48 hpi parasite
number and size of unﬁxed cells were determined by automated
microscopy (INcell Analyzer, 2000, Gelifesciences). At 65 hpi de-
tached cells (DC) were transferred to new wells and counted by
ﬂuorescent microscopy (Leica DMI 6000B). The detached cell assay
is presented as detached cell formation rate (DC number in % of
48 h number). Statistical analysis was done by performing One-way
ANOVA with Dunnet's Multiple Comparisons (Prism, GraphPad)
(*p < 0.05, **p < 0.01, ***p < 0.001, ns/not signiﬁcant > 0.05).
4.5. Isolated rat heart experiments
4.5.1. Animals
All animal care and experimental protocols conformed to the
European Union Guidelines for the Care and the Use of Laboratory
Animals (European Union Directive, 2010/63/EU) and were
approved by the Italian Department of Health (666/2015-PR). Male
Wistar rats (300e350 g, Charles River Italia, Calco, Italy) were
anaesthetized (i.p.) with a mixture of Zoletil® 100 (7.5 mg/kg
tiletamine HCl þ 7.5 mg/kg zolazepam HCl; Virbac srl, Milano) e
Rompun® (4mg/kg xylazine HCl; Bio 98, San Lazzaro, Bologna),
containing heparin (5000 U/kg), decapitated and exsanguinated.
4.5.2. Isolated rat heart preparation and perfusion
The hearts, spontaneously beating, were rapidly explanted and
mounted on a Langendorff apparatus for retrograde perfusion via
the aorta at a constant ﬂow rate of 10mL/min with a
KrebsHenseleit solution of the following composition (mM): NaCl
118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2, glucose
11.5, Na pyruvate 2, and EDTA 0.5, bubbled with a 95% O25% CO2
gasmixture (pH 7.4), and kept at 37 C, as described elsewhere [59].
The hearts were allowed to equilibrate for at least 20min before
drug exposure. Heart contractility was measured as LVP by means
of latex balloon, inserted into the left ventricle via the mitral valve
and connected to a pressure transducer (BLPR, WPI, Berlin, Ger-
many). The balloon was inﬂated with deionized water from a
microsyringe until a left ventricular end diastolic pressure of
10mmHg was obtained. Alteration in CPP, arising from changes in
coronary vascular resistance, were recorded by pressure transducer
(BLPR, WPI, Berlin, Germany) placed in the inﬂow line. A surface
ECG was recorded at a sampling rate of 1 kHz by means of two steel
electrodes, one placed on the apex and the other on the left atrium
of the heart. The ECG analysis included the following measure-
ments: RR (cycle length), HR (frequency), PQ (atrioventricular
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(overall action potential duration) [60]. LVP, CPP, and ECG were
recorded with a digital PowerLab data acquisition system (Power-
Lab 8/30; ADInstruments, Castle Hill, Australia) and analyzed by
using Chart Pro for Windows software (PowerLab; ADInstruments,
Castle Hill, Australia). LVP was calculated by subtracting the left
ventricular diastolic pressure from the left ventricular systolic
pressure. As the QT interval is affected by heart rate changes (e.g., it
shortens when heart rate increases), Bazett's formula normalized to
average rat RR (corrected QT, QTc¼QT/(RR/f)1/2) [61] was
routinely used to correct it, in order to avoid confounding effects. In
our experiments, “f”, the normalization factor according to the
basal RR duration was 242.23ms for compound 1 and 217.15ms for
compound 25, as it was the average cardiac cycle length. Analysis of
data was accomplished using GraphPad Prism version 5.04
(GraphPad Software, San Diego, USA). Statistical analyses and sig-
niﬁcance as measured by repeated measures ANOVA (followed by
Dunnett's post test) were obtained using GraphPad InStat version
3.06 (GraphPad Software, San Diego, USA). In all comparisons,
P< 0.05 was considered signiﬁcant. Compounds 1 and 25 were
dissolved in DMSO. Solvent failed to alter the response of the
preparations (data not shown).
4.6. Electrophysiological experiments
4.6.1. Cell isolation procedure and whole-cell patch-clamp
recording
Rat tail was cut immediately, cleaned of skin and placed in
physiological solution (namely external solution). The tail main
artery was dissected free of its connective tissue and cells or rings
prepared as detailed below. Smooth muscle cells were freshly iso-
lated from the tail main artery under the following conditions: a 5-
mm long piece of artery was incubated at 37 C for 40e45min in
2mL of 0.1mM Ca2þ external solution (in mM: 130 NaCl, 5.6 KCl, 10
Hepes, 20 glucose, 1.2 MgCl2, and 5 Na-pyruvate; pH 7.4) containing
20mM taurine (prepared by replacing NaCl with equimolar
taurine), 1.35mg/mL collagenase (type XI), 1mg/mL soybean
trypsin inhibitor, and 1mg/mL bovine serum albumin (Sigma Chi-
mica, Milan, Italy), which was gently bubbled with a 95% O2 e 5%
CO2 gas mixture to gently stir the enzyme solution, as previously
described [62]. Cells, stored in 0.05mM Ca2þ external solution
containing 20mM taurine and 0.5mg/mL bovine serum albumin at
4 C under normal atmosphere, were used for experiments within
two days after isolation [63]. Cells were continuously superfused
with external solution containing 0.1mM Ca2þ and 30mM tetrae-
thylammonium (TEA, Sigma Chimica, Milan, Italy) using a peri-
staltic pump (LKB 2132, Bromma, Sweden), at a ﬂow rate of 400 mL/
min. The conventional whole-cell patch-clamp method was
employed to voltage-clamp smooth muscle cells. Recording elec-
trodes were pulled from borosilicate glass capillaries (WPI, Berlin,
Germany) and ﬁre-polished to obtain a pipette resistance of
2e5MU when ﬁlled with internal solution. The internal solution
(pCa 8.4) consisted of (in mM): 100 CsCl, 10 HEPES, 11 EGTA, 2
MgCl2, 1 CaCl2, 5 Na-pyruvate, 5 succinic acid, 5 oxaloacetic acid, 3
Na2-ATP and 5 phosphocreatine; pHwas adjusted to 7.4 with CsOH.
An Axopatch 200B patch-clamp ampliﬁer (Molecular Devices Cor-
poration, Sunnyvale, USA) was used to generate and apply voltage
pulses to the clamped cells and record the corresponding mem-
brane currents. At the beginning of each experiment, the junction
potential between the pipette and bath solution was electronically
adjusted to zero. Current signals, after compensation for whole-cell
capacitance and series resistance (between 70% and 75%), were
low-pass ﬁltered at 1 kHz and digitized at 3 kHz prior to being
stored on the computer hard disk. Electrophysiological responses
were tested at room temperature (20e22 C). The current throughCav1.2 channels was recorded in external solution containing
30mM TEA and 5mM Ba2þ. Current was elicited with 250-ms
clamp pulses (0.067Hz) to 0mV from a Vh of 50mV. Data were
collected once the current amplitude had been stabilized (usually
7e10min after the whole-cell conﬁguration had been obtained).
Under these conditions, the current did not run down during the
following 40min [64]. Kþ currents were blocked with 30mM TEA
in the external solution and Csþ in the internal solution. Current
values were corrected for leakage and residual outward currents
using 10 mM nifedipine (Sigma Chimica, Milan, Italy), which
completely blocked ICa1.2. The osmolarity of the 30mM TEA- and
5mM Ba2þ-containing external solution (320 mosmol) and that of
the internal solution (290 mosmol) were measured with an
osmometer (Osmostat OM 6020, Menarini Diagnostics, Florence,
Italy). Acquisition and analysis of data were accomplished using
pClamp 9.2.1.9 software (Molecular Devices Corporation, Sunny-
vale, USA) and GraphPad Prism version 5.04 (GraphPad Software,
San Diego, USA). Compounds 1 and 25 were dissolved in DMSO
(below 0.01). Solvent failed to alter the response of the preparations
(data not shown).
4.7. Enzyme assays and IC50 analysis
For biochemical analysis of compounds, PfPMTwas expressed in
and puriﬁed from E. coli, as previously described [53]. Methyl-
transferase activity was monitored using a radiochemical assay
[52]. Standard reaction conditions were 0.1M Hepes KOH (pH 8.0),
2mM Na2EDTA, 10% (v/v) glycerol, 5% (v/v) DMSO, 30 mM SAM
(100 nCi of [methyl-14C] SAM), and 55 mM phosphoethanolamine in
100 mL with 2 mg of puriﬁed protein. Initial screening of compounds
1, 24, 25 and 48 as potential PfPMT inhibitors was performed at
100 mM. For determination of the IC50 for compound 25 versus
PfPMT, assays were performed with varied inhibitor concentration
(0e250 mM; ﬁnal 5% (v/v) DMSO) with 100% activity deﬁned as the
control reaction (conditions as above)). Data were plotted as per-
centage of activity versus inhibitor concentration and were ﬁt to
y ¼ 100/(1 þ ([I]/IC50)) using Kaleidagraph (Synergy Software),
where IC50 is the inhibitor concentration at 50% activity.
4.8. Computational details
All calculations in this work were performed on a system
comprising 72 Intel Xeon E5-2695 v4@2.10 GHz processors and two
NVIDIA GeForce 1070 GTX GPU with Ubuntu 16.04 LTS (long-term
support) operating system, running Schr€odinger Molecular
Modelling Environment Release 2015. Among the software in the
molecular modelling suite we used Maestro, version 10.1; Macro-
Model, version 10.7; LigPrep, version 3.3; SiteMap version 3.4;
Glide, version 6.6; Prime version 4.1 and PyMOL v1.8.4.0.
4.8.1. Protein and ligands preparation
We retrieved from the PDB database all proteins relevant for the
Plasmodium biology for a total of 108 crystal structures. All the
crystal structures were analyzed, removing the water molecules,
ions not involved in the enzymatic reactions andmolecules used for
the crystallization process. For the proteins with the co-crystallized
ligands (inhibitors, substrates etc) we extracted them for a re-
docking procedure to assess the reliability of the docking protocol
(see next paragraph for further details). The selected crystal
structures were prepared by means of Protein Preparation Wizard
(PPW) protocol implemented in Maestro, for acquiring appropriate
starting complexes for the subsequent computational analyses. In
particular, the protocol includes three steps to: (1) add hydrogens,
(2) optimize the orientation of hydroxyl groups, Asn, and Gln, and
the protonation state of His, and (3) perform a constrained
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consisting of a cycles of energy minimization based on the impact
molecular mechanics engine employing OPLS_2005 as force ﬁeld.
Regarding PfPMT, the crystal structurewith the code 3UJ8 from PDB
containing the inhibitor sinefungin (adenosyl-ornithine) was
selected. For the redocking procedure we consider also the natural
substrate SAM extracted from the PfPMT crystal structure 3UJ6.
Compounds 1 and 25 as well as all the ligands in the Plasmodium
proteins (Sinefungin and SAM in the case of PfPMT) were treated by
means of MacroModel for retrieving the lower energy conformers
to use as input in molecular docking experiments. The calculation
was performed using OPLS-2005 as force ﬁeld. The Generalized-
Born/Surface-Area (GB/SA) model for simulating the solvent effects
was used. No cutoff for non-bonded interactions was used. PRCG
method was employed with 1000 maximum iterations and 0.001
gradient convergence threshold for performing the molecular en-
ergy minimizations. MCMM (Monte Carlo Multiple Minimum) was
employed as torsional sampling method for the conformational
searches, performing automatic setup with 21 kJ/mol (5.02 Kcal/
mol) in the energy window for saving structure and 0.5Åwas used
as cutoff distance for redundant conformers. The lower conformers
were treated by LigPrep application, generating the most plausible
ionization state at cellular pH value (7.4± 0.2).
4.8.2. Molecular docking
Molecular Docking was carried out by Glide using the ligands
and the protein prepared as above-mentioned, applying Glide extra
precision (XP) method. Energy grid was prepared using default
value of protein atom scaling factor (1.0Å) within a cubic box
centered on the crystallized ligands were present, while for the
Plasmodium proteins without any ligand we selected the binding
site by analysing the literature data and/or performing a SiteMap
calculation to ﬁnd potential binding sites. Considering PfPMT, the
cubic box centered on the sinefungin. After grid generation, the
ligands and the crystallized inhibitor were docked into the en-
zymes with default parameters (no constraints were added). The
number of poses entered to post-docking minimization was set to
50. Glide XP score was evaluated. The interactions of compounds
with proteins were assessed using ligand-interaction diagram and a
script for displaying hydrophobic interactions (dis-
play_hydrophobic_interactions.py) downloaded from Schr€odinger
website and implemented in Maestro. The RMSD between the
docked poses and the co-crystallized compounds was calculated by
using the script rmsd. py available in Maestro. We chose the Glide
XP protocol since it demonstrated in this virtual screening pro-
cedure better accuracy in retrieving the binding mode of the
crystallized ligands, showing lower RMSD over the Glide standard
precision (SP) protocol as highlighted also for PfPMT. In fact,
although the docking protocols were able to correctly accommo-
date the considered ligands (sinefungin and SAM), the Glide XP
protocol showed low RMSD between the docked poses and crys-
tallized ligands (sinefungin Glide XP RMSD¼ 0.21; Glide SP
RMSD¼ 0.66. SAM Glide XP RMSD¼ 0.48; Glide SP RMSD¼ 1.05).
4.8.3. Evaluation of ligand binding energy
The Prime/MM-GBSA method (Prime software) computes the
difference between both the states, free and complex, of the ligand
and the protein after energy minimization as reported [50]. The
calculated absolute values are not necessarily in agreement with
observed binding afﬁnities. Nonetheless, the ranking of the ligands
based on the binding energies calculations (MM/GBSA DGbind) can
agree reasonably well with ranking based on observed binding
afﬁnity, particularly in the case of congeneric series. As the MM/
GBSA binding energies are approximate free energies of binding, a
more negative value indicates stronger binding. The technique wasused on the docked complexes (ligand-protein). For each ligand the
software was employed to assess its ligand binding energy (DGbind)
exploiting the following equation:
DGbind ¼ DEMM þ DGsolv þ DGsa
DEMM is the difference in the minimized energies calculated for the
complex and the sum of the energies of the unbounded protein and
ligand. DGsolv represents the difference in the GBSA solvation en-
ergy of the complex and the sum of these energies for the un-
bounded protein and ligand. DGSA is the difference in the surface
area (SA) energies for the complex and the sum of the SA energies
for the unbounded protein and ligand.
4.8.4. Picture preparation
Fig. 6 was prepared by means of PyMOL (The PyMOL Molecular
Graphics System, v1.8.4.0, Schr€odinger LLC, New York, 2015).
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